

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017264
Article Type:	Research
Date Submitted by the Author:	11-Apr-2017
Complete List of Authors:	Thavorn, Kednapa; The Ottawa Hospital Research Institute; Institute for Clinical Evaluative Sciences, ICES @uOttawa Maxwell, Colleen; University of Waterloo, Schools of Pharmacy; Institute for Clinical Evaluative Sciences Gruneir, Andrea; University of Alberta, Department of Family Medicine; Institute for Clinical Evaluative Sciences Bronskill, Susan; Institute for Clinical and Evaluative Sciences ; University of Toronto, Canada Bai, YuQing; Institute for Clinical and Evaluative Sciences Koné Pefoyo, Anna; Lakehead University, Department of Health Sciences; University of Toronto, Dalla Lana School of Public Health Petrosyan, Yelena; University of Toronto, Institute of Health Policy, Management and Evaluation Wodchis, Walter; University of Toronto, Institute of Health Policy Management and Evaluation
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health economics
Keywords:	multimorbidity, health system cost, socio-demographic factors, population-based study, publicly funded healthcare system

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study

Kednapa Thavorn PhD^{1,2,3}, Colleen J. Maxwell PhD^{3,4}, Andrea Gruneir PhD^{3,5,6,7}, Susan E. Bronskill PhD^{3,5},
YuQing Bai MSc³, Anna J. Koné Pefoyo PhD^{8,9}, Yelena Petrosyan MD, MPH, PhD⁵,
Walter P. Wodchis PhD^{*3,5,10}

1 Ottawa Hospital Research Institute, The Ottawa Hospital;
2 School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa;
3 Institute for Clinical Evaluative Sciences;
4 Schools of Pharmacy, University of Waterloo;
5 Institute of Health Policy, Management and Evaluation, University of Toronto;
6 Women's College Research Institute, Women's College Hospital;
7 Department of Family Medicine, University of Alberta;
8 Department of Health Sciences, Lakehead University;
9 Dalla Lana School of Public Health, University of Toronto;
10. Toronto Rehabilitation Institute

Kednapa Thavorn, PhD
Ottawa Hospital Research Institute,
The Ottawa Hospital, 501 Smyth Road,
PO Box 201B, Ottawa, ON, Canada K1H 8L6
Email: kthavorn@ohri.ca

Colleen J. Maxwell, PhD
School of Pharmacy, University of Waterloo
10A Victoria St. S., PHR 4013
Kitchener, Ontario, Canada N2G 1C5
Email: colleen.maxwell@uwaterloo.ca

Andrea Gruneir PhD
Department of Family Medicine
Faculty of Medicine and Dentistry
6-40 University Terrace
Edmonton, Alberta Canada T6G 1C9
Email: gruneir@ualberta.ca

Susan E. Bronskill PhD
Institute for Clinical and Evaluative Sciences
G1 06, 2075 Bayview Avenue
Toronto, Ontario, Canada M4N 3M5
Email: susan.bronskill@ices.on.ca

1
2
3
4
5
6 YuQing Bai, MSc
7 Institute for Clinical and Evaluative Sciences (ICES UofT)
8 155 College Street, Suite 424
9 Toronto, Ontario, Canada M5T 3M6
10 **Email:** yuqing.bai@utoronto.ca
11

12
13 Anna J. Koné Pefoyo, PhD
14 Department of Health Sciences
15 Lakehead University
16 955 Oliver Rd
17 Thunder Bay, Ontario, P7B 5E1 Canada
18 **Email:** akonepe@lakeheadu.ca
19

20
21 Yelena Petrosyan, PhD
22 Institute of Health Policy, Management and Evaluation
23 155 College Street
24 Toronto, Ontario, Canada M5T 3M6
25 **Email:** yelena.petrosyan@mail.utoronto.ca
26
27

28
29 Walter P. Wodchis, PhD, MAE, MA
30 Associate Professor
31 Institute of Health Policy, Management and Evaluation
32 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5 Canada
33 **Email:** walter.wodchis@utoronto.ca
34

35 ***Correspondence:**

36 **Address:**

37 Walter P. Wodchis, PhD, MAE, MA
38 Associate Professor
39 Institute of Health Policy, Management and Evaluation
40 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5
41 **Tel:** 416-946-7387
42 **Email:** walter.wodchis@utoronto.ca
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To estimate the attributable costs of multimorbidity and assessed whether the association between the level of multimorbidity and health system costs varies by socio-demographic factors in young (<65) and older (≥ 65) adults living in Ontario, Canada.

Design: a population-based, cross-sectional study

Setting: the province of Ontario, Canada

Participants: 6,639,089 Ontarians who were diagnosed with at least one of 16 selected chronic conditions on April 1, 2009.

Main outcome measures: From the perspective of the publicly funded healthcare system, total annual healthcare costs were derived from linked provincial health administrative databases using a person-level costing method. We used the generalized linear models to examine the association between the level of multimorbidity and healthcare costs and the extent to which sociodemographic variables modified this association.

Results: Attributable total costs of multimorbidity ranged from \$377 to \$2,073 for young individuals and \$1,026 to \$3,831 for older adults. The association between the degree of multimorbidity and healthcare costs was significantly modified by age ($p < 0.001$), sex ($p < 0.001$) and neighborhood income ($p < 0.001$) in both age groups. The rate of increase in healthcare costs with greater number of chronic conditions was more gradual in women than men aged 65 years or younger. For those older than 65 years, the rate of increase was less pronounced among women living with fewer than 3 chronic conditions but significantly greater among those experiencing 3+ chronic conditions compared to men. We also observed that the positive association between the level of multimorbidity and health care costs was significantly accelerated by greater levels of marginalization.

1
2
3
4
5
6
7 **Conclusion:** Socio-demographic factors are important effect modifiers of the relationship
8
9 between multimorbidity and healthcare costs; they should be considered in any discussion on the
10
11 implementation of healthcare policies and the organization of healthcare services aimed at
12
13 controlling healthcare costs associated with multimorbidity.
14
15

16
17
18 **KEYWORDS:** multimorbidity, health system costs, socio-demographic factors, population-
19
20 based study, publicly funded healthcare system
21
22

23 **Word Counts:** 296 (abstract), 3,841 (main text without tables)
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This population-based study was based on a large sample size and used the robust costing and generalized linear model regression techniques.
- The availability of linked and patient-level health administrative databases allows us to estimate the total health system costs associated with multimorbidity from all healthcare sectors.
- The use of health administrative databases can also minimize potential recall and non-response biases that are commonly found in survey data.
- The total healthcare costs reported in this study may be underestimated because they were derived based on selected 16 chronic conditions. Moreover, it was not possible to measure some costs (e.g., deductibles and co-payments borne by supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated with caregiving) with our data.
- The study did not take into account the clusters of chronic conditions. It is possible that the relationship between multimorbidity and healthcare costs may vary according to the type and patterns of comorbid chronic conditions.

BACKGROUND

Multimorbidity, the presence of the two or more co-existing conditions within a single person, is increasingly prevalent due to advances in life-extending medical treatments and increases in life expectancy. (1, 2) Internationally, the prevalence of multimorbidity has been shown to range from 17% in young adults (3) to 82% in older adults living in nursing homes.(4) In Canada, the prevalence of multimorbidity based on 16 selected conditions in Ontario rose from 17.4% in 2003 to 24.3% in 2009, and this increase was evident across all age groups.(5)

Higher levels of multimorbidity are associated with impaired physical functioning (6), poorer quality of life (7), more frequent use of health services, and higher risk of death. (8) In addition, individuals with multimorbidity may experience faster disease progression and require complex medical care services. (9) These individuals may be at a higher risk of receiving sub-optimal care (10), inappropriate prescriptions (11) and experience potentially preventable hospitalizations. (12) These adverse health outcomes can impose substantial burden on patients, family caregivers and the healthcare system.

The relationship between multimorbidity and healthcare costs is well-documented and has been shown to be curvilinear or exponential across jurisdictions. The average Medicare payments in the US ranged from \$1,154 among Part A and Part B beneficiaries with one chronic condition to \$13,973 among beneficiaries with at least four chronic conditions (a 12-fold difference). (12) Similarly, the mean total health system cost among older adults with multimorbidity in Switzerland was nearly six times higher than the those without multimorbidity. (13)

1
2
3
4
5 Despite an abundance of research describing the relationship between multimorbidity and
6
7 healthcare costs, existing studies have some important limitations. Some previous
8
9 multimorbidity studies failed to account for a positively skewed distribution of cost data leading
10
11 to several violations of modeling assumptions which could result in biased conclusions about the
12
13 significance of the effects. (14) Multimorbidity studies that did transform cost data to the
14
15 logarithmic scale may still be subject to a positive or negative bias of the predicted costs because
16
17 the exponentiation of the predicted values from a log-transformed regression model provides the
18
19 prediction of a median instead of arithmetic mean. (15) More importantly, the role of
20
21 sociodemographic characteristics as effect modifiers in the relationship between multimorbidity
22
23 and healthcare costs remains under-described, although previous research has shown that the
24
25 specific types of disease clusters vary by age and sex (2, 16) and that multimorbidity is more
26
27 prominent in selected visible minority and low-socioeconomic status populations. (17)
28
29
30
31
32
33
34

35 The objectives of this study were therefore to estimate the health system costs attributable to
36
37 multimorbidity and assess the extent to which the relationship between the level of
38
39 multimorbidity and health system costs varies according to sociodemographic characteristics.
40
41
42
43

44 **METHODS**

45 **Study design and sample**

46
47 This population-based, cross-sectional study included all residents who lived in the province of
48
49 Ontario between April 1, 2009 and March 31, 2010, were enrolled in Ontario Health Insurance
50
51 Plan (OHIP), and were diagnosed with at least one of the following selected 16 chronic
52
53 conditions: acute myocardial infarction (AMI), arthritis, asthma, cancer, cardiac arrhythmia,
54
55
56
57
58
59
60

1
2
3
4 chronic coronary syndrome, chronic obstructive pulmonary disorder (COPD), congestive heart
5
6 failure, dementia, depression, diabetes, hypertension, osteoporosis, renal failure , rheumatoid
7
8 arthritis and stroke. These conditions were selected because previous research and clinical
9
10 experts agreed that they were highly prevalent and imposed substantial care and economic
11
12 burden to Canada's healthcare system. (5, 18) Each condition was identified from multiple
13
14 provincial health administrative databases using diagnostic algorithms and consultation codes
15
16 that have been validated or used in previous studies. (19-21) The administrative databases were
17
18 linked anonymously using unique identifiers. They were housed and secured at the Institute for
19
20 Clinical Evaluative Sciences (ICES) under data security and privacy policies and procedures
21
22 approved by the Information and Privacy Commissioner of Ontario. This study was approved by
23
24 the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
25
26
27
28
29
30
31
32

33 We defined six conditions (AMI, asthma, chronic heart failure, COPD, diabetes, and
34
35 hypertension) based on validated population derived registries held at ICES. (22-28) These
36
37 conditions were all defined based on one diagnosis recorded in acute care or two diagnoses
38
39 recorded in ambulatory care (physician) records within a two-year period, except for AMI which
40
41 was defined using acute care records over a one-year period. A similar approach was adopted to
42
43 define the remaining chronic conditions including arthritis, cancer, cardiac arrhythmia, chronic
44
45 coronary syndrome, dementia, depression, osteoporosis, renal failure, rheumatoid arthritis and
46
47 stroke.
48
49
50
51
52
53

54 **Measures**

55 *Healthcare costs*

56
57
58
59
60

1
2
3
4 Healthcare costs were estimated from a perspective of the publicly funded healthcare system;
5
6 accordingly, only direct costs borne to the Ontario Ministry of Health and Long-Term Care were
7
8 considered. In Ontario, medically necessary hospital and physician services are paid for by the
9
10 publicly-financed health insurance plan. Public coverage for prescription drugs is primarily
11
12 limited to residents aged 65 years and over, social assistance recipients as well as those with high
13
14 prescription drug costs compared to their net household income.
15
16
17
18
19

20
21 We identified, measured and valued direct healthcare costs by applying a person-level costing
22
23 technique that was developed and validated based on the Ontario health administrative data. (29)
24
25 We calculated the costs of inpatient hospitalizations, emergency department visits, same day
26
27 surgeries, and inpatient rehabilitation by multiplying the weighted volume of services by the
28
29 average provincial costs per weighted case. We obtained the costs of fee-for-service physician
30
31 and outpatient diagnostic or laboratory services through OHIP fee approved as outlined in the
32
33 Ontario Health Insurance Schedule of Benefits and Fees. (30) We calculated non-fee-for-service
34
35 physician payments by applying applicable capitation payments or the median amount
36
37 reimbursed for the same service code for the specific fiscal year. (29) Costs for high-cost medical
38
39 device equipment were estimated from amount reimbursed to patients recorded in the Assistive
40
41 Devices Program database. Complex continuing care and inpatient psychiatric costs were based
42
43 on case mix, number of days in care, and Resource Utilization Groups. (31) Patient costs for
44
45 long-term care and home care were estimated using average cost per hour. We used pharmacy
46
47 payments recorded in the Ontario Drug Benefit database to capture prescription medication costs
48
49 for individuals eligible for public coverage. Annual total direct healthcare costs were the sum of
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 costs across healthcare sectors for each patient for a one-year period, i.e. from April 2009 to
5
6 March 2010.
7
8
9

10
11 We categorized healthcare costs into five components: physician, hospital, drug, continuing care
12 and other health care delivery costs. Physician costs included professional fees paid by the
13 provincial insurance plan directly to physicians in private practice. Hospital costs included
14 amounts paid to healthcare institutions, including those providing acute care, extended and
15 chronic care, rehabilitation and convalescent care, psychiatric care, as well as drugs dispensed in
16 hospitals. Drug costs consist of the costs for prescriptions dispensed at outpatient pharmacies to
17 individuals eligible for provincial coverage, while continuing care costs included expenditure on
18 home care and residential long-term (nursing-home) care. The other healthcare delivery costs
19 category represented expenditures on an assistive device program that subsidizes high-cost
20 equipment, such as wheel chairs, walkers, continuous positive airway pressure devices and
21 insulin pumps, for patients with physical disabilities. All costs were expressed in 2009 Canadian
22 Dollars.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 *Independent variables*

43
44 Multimorbidity was defined as the occurrence of two or more chronic diseases among the 16
45 selected conditions within a single individual and was categorized into five groups. A categorical
46 variable was created to capture those with no multimorbidity (single disease only), two, three,
47 four and five or more multimorbid conditions. Socio-demographic variables consisted of age,
48 sex, income and level of marginalization. As prescription drug costs among Ontarians aged less
49 than 65 years are primarily covered by private drug plans, we ran separate regressions for
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 younger (<65 years) and older (65+ years) cohorts. We also included a continuous variable of
5
6 age in the models. Income level was categorized to five quintiles, with the lowest quintile
7
8 reflecting the lower income level. We used the Ontario Marginalization Index, a validated
9
10 census- and geographically-based index, as a proxy for individual-level sociodemographic
11
12 factors. (32) The index consisted of four dimensions of marginalization: material deprivation;
13
14 residential instability; ethnic concentration; and dependency. Lower scores on each dimension
15
16 represent areas that are the least marginalized and higher scores represent areas that are the most
17
18 marginalized. This index has been shown to be associated with several health outcomes. (33)
19
20
21
22
23
24

25
26 We also controlled for other factors that might confound the impact of multimorbidity on
27
28 healthcare costs. Selection of such factors was guided by previous healthcare costs studies (12,
29
30 34, 35) and was subject to their availability in Ontario administrative databases. This
31
32 confounding factor included the type of primary care model and geographic location. The
33
34 primary care model was categorized into three groups: group-based teams with capitation/salary
35
36 and team-based payment (family health teams/other group models); capitation or blended
37
38 payment models (family health networks/family health organizations); or primarily fee for
39
40 service (family health groups and non-rostered patients). We assigned a geographic location to
41
42 each individual using the Rurality Index for Ontario (36), whereby a value greater than 40 was
43
44 considered to be a designated rural area.
45
46
47
48
49
50

51 52 **Analysis**

53
54 Annual health care costs per capita were described by health service sector, age group (<65 vs.
55
56 ≥65 years), the degree of multimorbidity and each of the independent factors, such as sex, age
57
58
59
60

1
2
3
4 groups, and the level of marginalization. Multivariate regression analyses were used to assess the
5
6 incremental costs of interest in this study. To identify the regression model that fits best with the
7
8 cost data, we followed the steps suggested by Manning and Mullahy. (37) We first ran ordinary
9
10 least-squares regressions (OLS) of the logarithmic transformation of cost data on the number of
11
12 chronic conditions and other confounding factors. However, the OLS regression was deemed
13
14 inappropriate because the residuals were not normally distributed. The generalized linear model
15
16 (GLM) with a log-link function and a gamma distribution was chosen because a modified Park
17
18 test suggested that the variance was proportional to the conditional mean. The GLM allows us to
19
20 estimate mean healthcare costs without the need for retransformation.
21
22
23
24
25
26
27

28
29 Attributable costs due to multimorbidity were estimated by subtracting the mean predicted cost
30
31 of one chronic condition from two conditions, two from three conditions, three from four
32
33 conditions, and four from at least five conditions, respectively. To investigate whether the
34
35 relationship between the level of multimorbidity and healthcare costs was moderated by
36
37 sociodemographic factors, we added an interaction term between the level of multimorbidity and
38
39 each sociodemographic factor at a time; for example, the level of multimorbidity*sex or the level
40
41 of multimorbidity*income level, to the adjusted model. The significance of each interaction term
42
43 was assessed by comparing the likelihood ratio of the full model with interaction terms to the
44
45 model without interaction terms using the likelihood ratio test.
46
47
48
49
50
51

52
53 The model performance, including goodness of fit and specifications, was examined by checking
54
55 the scaled deviance, Pearson's chi-square statistics and residual plots, respectively. All analyses
56
57
58
59
60

1
2
3
4 were performed using SAS statistical software for UNIX (version 9.3; SAS Institute, Cary, North
5
6
7 Carolina).

11 RESULTS

14 We identified a cohort of 6,639,089 individuals living with at least one of the selected 16 chronic
15
16 conditions in Ontario in 2009 (see Appendix 1 for baseline characteristics). Our cohort represents
17
18 about 50% of the total population in the province of Ontario in 2009. Close to half of the study
19
20 cohort (48%) had at least two selected chronic conditions, and this prevalence was found to
21
22 increase with age. The majority of the study cohort was female (53%) and was younger than 65
23
24 years of age (75%). Nearly all individuals (91%) resided in non-rural areas, and about one-third
25
26 (33%) lived in neighborhoods with a high proportion of diverse ethnic groups.
27
28
29

30
31
32
33 The total annual healthcare cost estimated for the study cohort was \$26.5 billion. As shown in
34
35 Figure 1, individuals living with at least two selected chronic conditions represented 23.7% of
36
37 total population but accounted for approximately two-third (67.9%) of total allocatable
38
39 healthcare costs. By contrast, individuals without multimorbidity who accounted for 76% of the
40
41 total population were responsible for only 32.1% of total allocatable healthcare costs. On
42
43 average, annual total costs per capita amounted to \$2,217 in individuals younger than 65 years
44
45 and \$9,398 in those aged 65 years or older.
46
47
48

49 [Figure 1]

50
51
52 Table 1 shows the annual total costs per capita by baseline characteristics for young and older
53
54 adults. For both age groups, per capita total healthcare costs were higher in women than men.
55
56 The average healthcare costs increased with older age. The greater levels of marginalization
57
58
59
60

were associated with higher healthcare costs in both age groups. Mean total healthcare costs were the highest among individuals living in the most deprived and most unstable areas as well as those who were highly dependent. However, mean total costs decreased with higher income level.

Table 1. Annual per capita healthcare costs by baseline characteristics and age group, April 1, 2009 to March 31, 2010

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
All cohort	5,004,699	2,217 (9630)	502 (193-1317)	1,634,390	9,398 (19,796)	2,982 (1,448-7,178)
Sex						
Female	2,618,591	2,311 (9,044)	624 (248– 1,546)	923,053	9,526.96 (19,245)	2,991.97 (1,461-7,344)
Male	2,386,108	2,113 (10,233)	378.67 (132– 1,058)	711,337	9,230.31 (20,488)	2,968.13 (1,431-6,982)
Age group (years)						
<20	809,782	997 (6,420)	257 (103-600)			
20 - 44	1,784,314	1,835 (7,997)	440 (155-1,171)			
45 – 64	3,247,243	2,910 (11,414)	684 (291-1,725)			
65 - 74				1,219,877	6,424 (16,464)	2,363 (1,173-4,757)
75+				797,750	12,517 (22,351)	3,964 (1,884-12,277)
Income quintile						
Lowest	935,048	2,822 (11,333)	580 (206-1699)	314,616	10,646 (21,501)	3,325 (1,596-8,667)
Middle-low	970,797	2,360 (10,276)	521 (199-1,380)	336,928	9,529 (20,218)	3,053 (1,501-7,296)
Middle	999,087	2,107 (9,146)	498 (195-1,268)	318,557	9,319 (19,552)	2,992 (1,470-7,114)
Middle-high	1,042,284	2,008 (8,899)	487 (195-1,226)	322,798	9,120 (19,279)	2,916 (1,426-6,873)
Highest	1,009,89	1,903 (8,391)	475	331,022	8,549	2,747

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
	0		(192-1,180)		(18,309)	(1,351-6,352)
Rurality index						
Non-rural	4,579,691	2,206 (9,605)	509 (197-1,320)	1,459,014	9,448 (19,998)	3,005 (1,470-7,161)
Rural	356,361	2,522 (10,112)	501 (197-1,441)	157,864	9,333 (18,303)	2,918 (1,400-7,798)
Deprivation quintile						
Least deprived	1,282,898	1,894.17 (8,596.59)	476 (193-1,170)	371,547	9,167 (19,628)	2,823 (1,380-6,709)
Less deprived	1,136,731	2,015 (8,810)	489 (196-1,231)	368,124	8,935 (18,928)	2,898 (1,423-6,759)
Somewhat deprived	982,133	2,193 (9,240)	504 (196-1,311)	346,326	9,165 (19,300)	2,978 (1,463-7,030)
Very deprived	808,152	2,438 (10,281)	511 (200-1,443)	293,434	9,541 (19,951)	3,100 (1,520-7,467)
Most deprived	705,593	2,941 (11,861)	600 (210-1,79)	228,501	10,517 (21,250)	3,326 (1,599-8,570)
Instability quintile						
Least dependent	1,211,734	2,007 (8,674)	489 (188-1,250)	188,787	8,149 (19,413)	2,713 (1,307-5,882)
Less dependent	1,179,936	2,078 (9,134)	500 (195-1,275)	276,819	8,359 (18,652)	2,777 (1,353-6,167)
Somewhat dependent	976,538	2,230 (9,793)	506 (198-1,320)	303,853	8,717 (19,018)	2,849 (1,401-6,548)
Very dependent	808,196	2,349 (9,954)	515 (201-1,375)	326,662	9,068 (19,195)	2,944 (1,458-6,958)
Most dependent	739,103	2,650 (10,947)	550 (213-1,507)	511,811	10,961 (20,953)	3,381 (1,636-9,336)
Ethnic concentration quintile						
Lowest	564,476	2,398 (9,766)	500 (200-1,370)	283,980	9,309 (18,529)	2,983 (1,463-7,533)
Middle-low	756,120	2,288 (9,552)	491 (196-1,317)	304,526	9,170 (18,773)	2,969 (1,458-7,283)
Middle	854,573	2,280 (9,780)	497 (196-1,317)	305,524	9,540 (19,678)	3,011 (1,478-7,419)
Middle-high	1,028,876	2,190 (9,565)	502 (195-1,309)	294,164	9,600 (20,240)	3,012 (1,473-7,266)
Highest	1,711,462	2,124 (9,468)	528 (199-1,331)	419,738	9,288 (20,751)	2,981 (1,441-6,694)

Note: SD, standard deviation; IQR, interquartile range

1
2
3
4
5
6
7 Figure 2 illustrates the distribution of total cost per capita by type of services. Among individuals
8
9 younger than 65 years of age, hospitalization was the primary cost driver and responsible for
10
11 47% of total healthcare costs, followed by physician costs (32%), drug costs (10%), and
12
13 continuing care costs (6%). For older adults, hospital costs remained the largest cost component
14
15 (41%), followed by continuing care costs (23%), drug costs (19%) and physician costs (15%).
16
17 Figure 2 also reveals that unadjusted mean total costs increased at an increasing rate with
18
19 additional numbers of chronic conditions, ranging from \$1,352 in individuals younger than 65
20
21 years of age without multimorbidity to \$13,105 in those living with five or more chronic
22
23 conditions, corresponding to a 10-fold increase. On the other hand, while \$4,185 was spent on
24
25 older adults without multimorbidity, spending increased by about 5-fold to \$19,196 in those
26
27 living with five or more chronic conditions.
28
29
30
31

32 [Figure 2]
33
34

35 Table 2 shows adjusted attributable costs of multimorbidity after controlling for other factors.
36
37 Among individuals younger than 65 years, the attributable total cost was \$377 in those living
38
39 with two chronic conditions and \$2,073 in those living with at least 5 chronic conditions,
40
41 corresponding to a six times higher attributable cost. Similarly, attributable total costs in older
42
43 adults also rose with increasing number of chronic conditions, ranging from \$1,026 in those with
44
45 two chronic conditions to \$3,831 in those with five or more. The magnitude of an incremental
46
47 cost depended on a reference category. Specifically, one additional chronic condition to young
48
49 adults without multimorbidity led to an attributable cost of \$377, while for young adults who
50
51 already had three chronic conditions, one more health condition incurred additional \$798. These
52
53 incremental costs were even greater in older adults, whereby an incremental cost rose from
54
55
56
57
58
59
60

1
2
3
4 \$1,026 (1 vs. 2 conditions) to \$1,652 (3 vs. 4 conditions). Similar patterns were observed for
5
6 subdivided health care costs, which varied across age groups [Table 2]. An additional chronic
7
8 condition caused 1- to 3-fold increase in the costs of each health sector except for hospital
9
10 whereby incremental costs increased steady from \$185 to \$802 in the younger cohort and from
11
12 \$232 to \$1,060 in the older adult cohort.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Table 2.** Adjusted incremental total healthcare costs by the degree of multimorbidity and age group*, April 1, 2009 to March 31, 2010

conditions	< 65 years (N=5,004,699)						≥ 65 years (N=1,634,390)					
	total	physician	hospital	drug	continuing care	others	total	physician	hospital	drug	continuing care	others
2 vs. 1	376.50	200.26	185.12	232.37	288.71	23.96	1,025.76	166.48	231.60	350.29	254.14	23.54
3 vs. 2	534.34	238.28	207.22	252.84	207.83	23.81	1,279.96	201.20	247.76	403.56	314.91	28.51
4 vs. 3	798.03	286.29	264.75	316.43	234.58	24.67	1,651.92	227.04	353.60	429.01	367.45	33.17
≥5 vs. 4	2,072.57	515.80	801.64	666.13	486.58	37.64	3,831.40	400.57	1060.00	673.89	732.19	63.76

2 *adjusted for sex, age, income quintile, primary care model, rurality index, deprivation quintile, instability quintile, dependency quintile, and ethnic

3 concentration quintile

1
2
3 14 We also found that the association between number of chronic conditions and health care cost
4
5 15 was significantly modified by age and sex for both young and older adults [Table 3]. Older age
6
7
8 16 was associated with a reduced rate of increase in health care cost with increasing levels of
9
10 17 multimorbidity for individuals aged 65 years or younger but accelerated the rate of increase in
11
12 18 those aged 65 years or older. In addition, the rate of increase in health care costs was more
13
14
15 19 gradual in women aged 65 years or younger than their male counterparts. For those aged 65
16
17 20 years or older, the health care cost associated with more chronic conditions rose more rapidly
18
19
20 21 than for men.
21
22
23

24 23 For both age groups, the rise in health care cost with greater level of multimorbidity was less
25
26 24 pronounced among individuals with high income level. The association between the level of
27
28 25 multimorbidity and health care cost was significantly modified by the level of deprivation,
29
30 26 instability, dependency and ethnic concentration. The positive association between the level of
31
32 27 multimorbidity and health care costs was stronger among individuals living in more deprived,
33
34 28 unstable, dependent or diverse ethnic groups than those living in less deprived, stable, dependent
35
36 29 or diverse ethnic concentration areas. We did not observe a significant interaction between the
37
38 30 number of chronic conditions and the level of dependency in the older adult cohort.
39
40
41
42

43 **Table 3.** Generalized linear models results for total healthcare costs[^]
44

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
Intercept	1.6844***	0.0007	1.6049***	0.0034
Age	0.0023***	0.0001	0.0053***	0.0001
Sex				
Male	reference		reference	
Female	0.0628***	0.0002	-0.0023***	0.0006
Number of chronic conditions				
1 condition	reference		reference	

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
2 conditions	0.1092***	0.0017	0.1068***	0.0044
3 conditions	0.2189***	0.0027	0.1860***	0.0045
4 conditions	0.3312***	0.0050	0.2563***	0.0049
≥5 conditions	0.4203***	0.0080	0.3772***	0.0048
Income quintile				
Lowest	reference		reference	
Middle-low	-0.0043***	0.0005	-0.0019*	0.0010
Middle	-0.0045***	0.0005	0.00014	0.0012
Middle-high	-0.0044***	0.0006	0.0001	0.0012
Highest	-0.0080***	0.0006	-0.0045***	0.0013
Deprivation quintile				
Least deprived	reference		reference	
Less deprived	-0.0006*	0.0004	-0.0014***	0.0008
Somewhat deprived	-0.0008*	0.0004	-0.0020**	0.0009
Very deprived	0.0022***	0.0005	-0.0009	0.0011
Most deprived	0.0135***	0.0006	0.0044***	0.0013
Instability quintile				
Least unstable	reference		reference	
Less unstable	0.0039***	0.0005	-0.0019**	0.0009
Somewhat unstable	0.0073***	0.0005	-0.0008	0.0009
Very unstable	0.0122***	0.0005	0.0031***	0.0009
Most unstable	0.0247***	0.0005	0.0087***	0.0010
Ethnic concentration quintile				
Lowest	reference		reference	
Middle-low	0.0002	0.0004	-0.0005	0.0009
Middle	0.0018***	0.0004	0.0022	0.0009
Middle-high	0.0047***	0.0004	-0.0007	0.0010
Highest	0.0066***	0.0004	-0.0043***	0.0009
Dependency quintile				
Least dependent	reference		reference	
Less dependent	0.0004	0.0004	0.0012**	0.0005
Somewhat dependent	0.0001	0.0004	0.0027***	0.0005
Very dependent	0.0009**	0.0004	0.0030***	0.0005
Most dependent	0.0020***	0.0005	0.0100***	0.0005
Number of chronic conditions * sex				
1 condition* Male	reference		reference	
2 conditions * Female	-0.0171***	0.0016	-0.0029***	0.0007
3 conditions * Female	-0.0396***	0.0011	-0.0022***	0.0008
4 conditions * Female	-0.0549***	0.0007	0.0001	0.0008
≥5 conditions * Female	-0.0659***	0.0005	0.0030***	0.0008
Number of chronic conditions * age				
1 condition * age	reference		reference	

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
2 conditions * age	-0.0171***	0.0016	-0.0006***	0.0001
3 conditions * age	-0.0396***	0.0011	-0.0010***	0.0001
4 conditions * age	-0.0549***	0.0007	-0.0014***	0.0001
≥5 conditions * age	-0.0659***	0.0005	-0.0023***	0.0001
Number of chronic conditions * income quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0016*	0.0009	-0.0025*	0.0013
3 conditions * middle-low	-0.0011	0.0013	-0.0037**	0.0014
4 conditions* middle-low	-0.0043**	0.0020	-0.0043**	0.0015
≥5 conditions* middle-low	-0.0031	0.0027	-0.0046**	0.0014
2 conditions*middle	-0.0020**	0.0010	-0.0032**	0.0015
3 conditions * middle	-0.0030**	0.0014	-0.0051**	0.0015
4 conditions* middle	-0.0053**	0.0023	-0.0055**	0.0017
≥5 conditions* middle	-0.0028	0.0031	-0.0072***	0.0016
2 conditions*middle-high	-0.0024**	0.0011	-0.0031*	0.0016
3 conditions * middle-high	-0.0032**	0.0016	-0.0052**	0.0016
4 conditions* middle-high	-0.0067**	0.0025	-0.0081***	0.0018
≥5 conditions* middle-high	-0.0093**	0.0034	-0.0070***	0.0018
2 conditions*highest	-0.0015	0.0011	-0.0036**	0.0017
3 conditions * highest	-0.0031*	0.0017	-0.0063***	0.0018
4 conditions* highest	-0.0096***	0.0027	-0.0088***	0.0019
5 conditions* highest	-0.0099**	0.0038	-0.0095***	0.0019
Number of chronic conditions * deprivation quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	0.0024***	0.0007	-0.0001	0.0011
3 conditions * middle-low	0.0038 ***	0.0010	-0.0015	0.0011
4 conditions* middle-low	0.0027	0.0017	-0.0016	0.0013
≥5 conditions* middle-low	0.0060**	0.0026	-0.0029**	0.0012
2 conditions*middle	0.0047***	0.0007	-0.0002	0.0012
3 conditions * middle	0.0067***	0.0010	-0.0018	0.0013
4 conditions* middle	0.0062***	0.0017	-0.0045**	0.0014
≥5 conditions* middle	0.0109***	0.0026	-0.0042**	0.0014
2 conditions*middle-high	0.0057***	0.0009	-0.0012	0.0014
3 conditions * middle-high	0.0071***	0.0014	-0.0031**	0.0015
4 conditions* middle-high	0.0074***	0.0022	-0.0051**	0.0016
≥5 conditions* middle-high	0.0111***	0.0032	-0.0079***	0.0016
2 conditions*highest	0.0073***	0.0011	-0.0028	0.0017
3 conditions * highest	0.0108***	0.0016	-0.0052**	0.0018
4 conditions* highest	0.0114***	0.0026	-0.0089***	0.0019
≥5 conditions* highest	0.0119***	0.0036	-0.0098***	0.0019
Number of chronic conditions * instability				
1 condition* lowest	reference		reference	

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
2 conditions*middle-low	-0.0012**	0.0007	0.0009	0.0011
3 conditions * middle-low	-0.0007	0.0010	0.0020	0.0012
4 conditions* middle-low	-0.0016	0.0017	0.0010	0.0013
≥5 conditions* middle-low	-0.0013	0.0026	0.0022	0.0014
2 conditions*middle	-0.0017**	0.0008	0.0037**	0.0014
3 conditions * middle	-0.0012	0.0012	0.0010	0.0013
4 conditions* middle	-0.0002	0.0019	0.0022	0.0014
≥5 conditions* middle	0.0025	0.0027	0.0037**	0.0014
2 conditions*middle-high	-0.0003	0.0009	0.0022*	0.0012
3 conditions * middle-high	0.0006	0.0012	0.0019	0.0013
4 conditions* middle-high	0.0011	0.0019	0.0033**	0.0014
≥5 conditions* middle-high	0.0075***	0.0027	0.0048***	0.0014
2 conditions*highest	0.0037***	0.0012	-0.0027**	0.0013
3 conditions * highest	0.0095***	0.0012	-0.0026**	0.0013
4 conditions* highest	0.0113***	0.0020	-0.0035**	0.0014
≥5 conditions* highest	0.0206***	0.0028	-0.0019	0.0014
Number of chronic conditions * ethnic concentration				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0006	0.0009	0.0011	0.0012
3 conditions * middle-low	-0.0007	0.0013	0.0022*	0.0012
Number of chronic conditions * ethnic concentration				
4 conditions* middle-low	-0.0020	0.0021	0.0012	0.0014
≥5 conditions* middle-low	0.0018	0.0029	0.0012	0.0013
2 conditions*middle	0.0004	0.0009	0.0006	0.0012
3 conditions * middle	-0.0006	0.0013	0.0003	0.0012
4 conditions* middle	-0.0034	0.0021	-0.0012	0.0014
≥5 conditions* middle	0.0016	0.0030	0.0004	0.0013
2 conditions*middle-high	0.0002	0.0009	0.0015	0.0012
3 conditions * middle-high	-0.0013	0.0014	0.0021*	0.0013
4 conditions* middle-high	-0.0056**	0.0022	0.0006	0.0014
≥5 conditions* middle-high	-0.0056*	0.0030	0.0035**	0.0014
2 conditions*highest	-0.0008	0.0012	0.0043***	0.0012
3 conditions * highest	-0.0021	0.0013	0.0047***	0.0013
4 conditions* highest	-0.0081***	0.0021	0.0044***	0.0013
≥5 conditions* highest	-0.0070**	0.0030	0.0093***	0.0013
Number of chronic conditions * dependency quintile[#]				
1 condition* lowest	reference		reference	
2 conditions*middle-low	0.0016**	0.0007		
3 conditions * middle-low	0.0018**	0.0010		
4 conditions* middle-low	0.0004	0.0017		
≥5 conditions* middle-low	-0.0028	0.0026		
2 conditions*middle	0.0015**	0.0001		

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
3 conditions * middle	0.0030***	0.0011		
4 conditions* middle	0.0036**	0.0018		
≥5 conditions* middle	0.0008	0.0025		
2 conditions*middle-high	0.0017**	0.0008		
3 conditions * middle-high	0.0029**	0.0012		
4 conditions* middle-high	0.0028	0.0019		
≥5 conditions* middle-high	0.0014	0.0027		
2 conditions*highest	0.0018**	0.0009		
3 conditions *highest	0.0032**	0.0013		
4 conditions* highest	0.0041**	0.0020		
≥5 conditions* highest	0.0038	0.0028		
AIC	15,672,974		5,058,276	
BIC	15,674,535		5,059,515	

^ adjusted for primary care models and rurality index; *** P < 0.001, ** P < 0.05, * p < 0.10; se indicates standard error; # interaction between the number of chronic conditions and dependency quintile was not statistically significant and therefore excluded from a final model.

DISCUSSION

Individuals living multimorbidity accounted for 79% of total healthcare costs incurred by our study cohort and 68% of total allocatable healthcare costs in Ontario in 2009. Although there is a growing body of literature documenting the economic burden of multimorbidity in other jurisdictions (12, 13, 38), the current study lends further evidence that small portion of the multimorbid population was responsible for a disproportionately high percentage of total healthcare costs. We observed this disproportionate relationship in both young (<65) and (65+) older cohorts, suggesting that any approaches to containing healthcare costs of multimorbidity should be implemented across all age groups.

Our study demonstrated that healthcare costs increased significantly with higher levels of multimorbidity. This positive association exists even after the adjustment for confounding factors and a skewed distribution of cost data using the generalized linear model with a log link function

1
2
3 49 and a gamma distribution. The exponential relationship between multimorbidity and incremental
4
5 50 healthcare costs shown in this study suggests that the financial burden of multimorbidity to the
6
7
8 51 healthcare system is not simply equal to the sum of costs incurred by each individual condition.
9
10 52 This non-linearity reflects the complex association of the degree of multimorbidity, the type of
11
12 53 disease clusters and healthcare costs. It is likely that patients with multimorbidity might
13
14 54 experience worse health outcomes and require more complex clinical management. (9) They are
15
16 55 also vulnerable to receiving redundant diagnostic tests (12), suboptimal transition of care and
17
18 56 inappropriate prescriptions. (11) This explanation is plausible as current treatment guidelines are
19
20 57 mainly focused on individual disease management. (10) Thus, as the number of healthcare
21
22 58 providers involved in the patient's care increases, information sharing and coordinating care
23
24 59 across health care providers may pose a challenge. (39) Moreover, an increasing number of
25
26 60 comorbid conditions may compromise patients' ability to self-manage their diseases. (40) The
27
28 61 high healthcare spending on multimorbidity found in our study underscores the need for ensuring
29
30 62 continuity and coordination of care in this population.
31
32
33
34
35
36
37
38
39 64 More importantly, our study contributes to the understanding of the association between the
40
41 65 degree of multimorbidity and healthcare costs. We observed that each unit increase in age
42
43 66 slowed the rise in health care costs with increasing number of chronic conditions in the young
44
45 67 cohort but accelerated the rise in health care costs in the older cohort. This highlighted that
46
47 68 multimorbidity had much larger impact on the youngest and oldest individuals. This age
48
49 69 difference might reflect the distribution of healthcare costs that are typically skewed to the first
50
51 70 year and the end of life. (41) Additionally, we found that healthcare costs in men increased faster
52
53 71 and surpassed the level in women as the number of chronic conditions increased in individuals
54
55
56
57
58
59
60

1
2
3 72 younger than 65 years. This sex difference might relate to different disease clusters whereby men
4
5 73 within this age group often experience life-threatening and more serious illnesses than women.
6
7
8 74 (42, 43) For those older than 65 years, the rate of increase in healthcare costs with the greater
9
10 75 level of multimorbidity were significantly higher in women than men. This sex difference could
11
12 76 be partially explained by longer life expectancy and greater risk of multimorbidity in older
13
14 77 women than men (17, 44), which may cause older women to be more dependent on formal (paid)
15
16 78 healthcare services and other informal (unpaid) caregivers.
17
18
19
20 79

21
22 80 Our results revealed that the association between the number of chronic conditions and
23
24 81 healthcare costs depended on neighborhood-level socioeconomic characteristics. Living in lower
25
26 82 income and marginalized area, i.e. greater levels of instability, dependency or ethnic
27
28 83 concentration, accelerated the rate of increase in health system costs with the greater level of
29
30 84 multimorbidity. This might reflect a higher risk of experiencing more complex multimorbid
31
32 85 conditions among individuals living in disadvantaged neighborhood (45) which led to greater
33
34 86 demand and utilization of healthcare. Another possible reason is that individuals living in more
35
36 87 deprived area may face barriers in accessing health services (46) and have delayed access to
37
38 88 preventive healthcare interventions or treatments (47), thereby having a higher risk of worse
39
40 89 health outcomes and high healthcare costs. As the neighborhood socioeconomic characteristics
41
42 90 were used in this study, the effect of these characteristics on the association between the number
43
44 91 of chronic conditions and healthcare costs should not be inferred to each individual.
45
46
47
48
49
50
51 92
52
53 93
54
55 94
56
57
58
59
60

95 **Strengths and limitations**

96 This population-based study was based on a large sample size and used the robust costing and
97 generalized linear model regression techniques. The availability of linked and patient-level
98 health administrative databases allows us to estimate the total health system costs associated with
99 multimorbidity from all healthcare sectors. The use of health administrative databases can also
100 minimize potential recall and non-response biases that are commonly found in survey data.

102 However, the results of this study should be interpreted in light of the following limitations.

103 First, we estimated healthcare costs based on selected 16 chronic conditions. The selection of a
104 limited number of chronic conditions is likely to underestimate the overall healthcare costs of
105 multimorbidity. However, total cost estimates reported in our study were comprehensive because
106 they amounted to 86% of total allocatable government expenditures in Ontario in 2009.(48)

107 Second, due to a paucity of data, some costs (e.g., deductibles and co-payments borne by
108 supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated
109 with caregiving) were excluded from the analysis. In addition, this study could not capture the
110 costs of medications covered by private sectors, including private insurers and out of pocket
111 expenses which represent the largest component of total prescription drug costs of Canadians
112 who are younger than 65 years of age. (49) For this reason, findings from this study may not be
113 generalizable to other jurisdictions with different healthcare systems.

115 Third, this study did not take into account the clusters of chronic conditions. It is possible that
116 the relationship between multimorbidity and healthcare costs may vary according to the type and
117 patterns of comorbid chronic conditions. However, previous research has shown that there were

1
2
3 118 no common clustering diseases among individuals living with multimorbidity (5) and that the
4
5 119 number chronic conditions had a stronger link to healthcare costs than the combination of
6
7
8 120 specific conditions. (50) Finally, due to the cross-sectional nature, our study may be subject to
9
10 121 simultaneity bias or endogeneity problem, and the estimated coefficient of multimorbidity on
11
12 122 healthcare costs may be biased and inconsistent. It is possible that having a greater number of
13
14 123 chronic conditions increases healthcare utilization and costs. At the same time, individuals who
15
16 124 had frequent contacts with the healthcare system might be more likely to be diagnosed with a
17
18 125 disease(s). Future longitudinal studies are required to attest a causal association between the
19
20 126 degree of multimorbidity and healthcare costs.
21
22
23
24
25
26

127

128 **CONCLUSION**

129 This cross-sectional, population-based study highlights the amount by which health system costs
130 increased significantly with increasing levels of multimorbidity in a publicly financed healthcare
131 system. The average and incremental healthcare costs reported in this study could serve as the
132 foundation for future health economic evaluation of interventions for preventing and managing
133 multimorbidity. As the relationship between multimorbidity and healthcare costs varies
134 according to socio-demographic factors, interventions addressing disparities in healthcare in
135 individuals living with multimorbidity may have a potential to reduce total health system costs.
136

137

138 **LIST OF ABBREVIATIONS**

139 AMI acute myocardial infarction

140 COPD chronic obstructive pulmonary disorder

GLM generalized linear model

1
2
3 141 ICES Institute for Clinical Evaluative Sciences
4

5 142 OHIP Ontario Health Insurance Plan
6
7

8 143 OLS ordinary least-squares regressions
9
10

11 144

12
13 **DECLARATIONS**

14
15 **Ethic approval:**

16
17 147 The study has been approved by the Research Ethics Board at Sunnybrook Health Sciences
18

19 148 Centre, Toronto, Ontario, Canada.
20
21

22 149

23
24 **Funding:**

25
26 151 This manuscript was supported through the Health System Performance Research Network
27

28 152 (HSPRN) by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC grant
29

30 153 #06034) and through provision of data by the Institute for Clinical and Evaluative Sciences with
31

32 154 funding from an annual grant by the Ministry of Health and Long-Term Care. The opinions,
33
34

35 155 results, and conclusions reported in this paper are those of the authors and are independent of the
36

37 156 funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or Ontario
38

39 157 MOHLTC is intended or should be inferred.
40
41

42 158

43
44
45 159 At the time this research was conducted, Dr. Thavorn was partially supported by the HSPRN
46

47 160 post-doctoral award and the Li Ka Shing post-doctoral award. None of the authors have any
48

49 161 conflicts of interest to report.
50
51

52 162

53
54
55 163 **Competing interests:** None
56
57
58
59
60

1
2
3 164 **Authors contributions:** WPW was the lead for the conception and creation of the cohort. YB
4
5
6 165 has created the cohorts through data linkages and helped with data analysis and methods. KT
7
8 166 interpreted the results and drafted the manuscript. CM, AG, SB, AK, YB, YP and WPW revised
9
10 167 the manuscript for important intellectual content and formatting. All authors read and approved
11
12
13 168 the final manuscript.

14
15 169
16
17 170 **Data sharing statement:** No additional data are available.
18
19

20 171

21
22 172

23
24 173

25
26 174

27
28 175

29
30 176

31
32 177

33
34 178

35
36 179

37
38 180

39
40 181

41
42 182

43
44 183

45
46 184

47
48 185

49
50 186

51
52
53
54
55
56
57
58
59
60

187 **REFERENCES**

- 188 1. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general
189 practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. *JCE*.
190 1998;51(5):367-75.
- 191 2. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last
192 20 years. *Eur J Gen Pract*. 2008;14 Suppl 1:28-32.
- 193 3. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs.
194 *JAMA*. 1996;276(18):1473-9.
- 195 4. Schram MT, Frijters D, van de Lisdonk EH, Ploemacher J, de Craen AJ, de Waal MW, et al.
196 Setting and registry characteristics affect the prevalence and nature of multimorbidity in the elderly. *JCE*.
197 2008;61(11):1104-12.
- 198 5. Kone Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The
199 increasing burden and complexity of multimorbidity. *BMC Public Health*. 2015;15(1):415.
- 200 6. Marengoni A, von Strauss E, Rizzuto D, Winblad B, Fratiglioni L. The impact of chronic
201 multimorbidity and disability on functional decline and survival in elderly persons. A community-based,
202 longitudinal study. *J Intern Med*. 2009;265(2):288-95.
- 203 7. Mondor L, Maxwell CJ, Bronskill SE, Gruneir A, Wodchis WP. The relative impact of chronic
204 conditions and multimorbidity on health-related quality of life in Ontario long-stay home care clients.
205 *Qual Life Res*. 2016. (10):2619-32.
- 206 8. St John PD, Tyas SL, Menec V, Tate R. Multimorbidity, disability, and mortality in community-
207 dwelling older adults. *Can Fam Physician*. 2014;60(5):e272-80.
- 208 9. Gijzen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and
209 consequences of comorbidity: a review. *JCE*. 2001;54(7):661-74.
- 210 10. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality
211 of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA*.
212 2005;294(6):716-24.

- 1
2
3 213 11. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the
4
5 214 elderly with diabetes: Identification of areas of potential treatment conflicts. *Diabetes Res Clin Pract.*
6
7 215 2010;87(3):385-93.
8
9
10 216 12. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple
11
12 217 chronic conditions in the elderly. *Arch Intern Med.* 2002;162(20):2269-76.
13
14 218 13. Bahler C, Huber CA, Brungger B, Reich O. Multimorbidity, health care utilization and costs in an
15
16 219 elderly community-dwelling population: a claims data based observational study. *BMC Health Serv Res.*
17
18 220 2015;15:23.
19
20 221 14. Jones AM, Rice N, dUva TB, Balia S. *Modelling health care costs.* Applied Health Economics. 2
21
22 222 ed. Oxford: Routledge; 2013.
23
24 223 15. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization
25
26 224 and costs. *Annu Rev Public Health.* 1999;20:125-44.
27
28 225 16. Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, et al. Prevalence
29
30 226 of multimorbidity in a geographically defined American population: patterns by age, sex, and
31
32 227 race/ethnicity. *Mayo Clin Proc.* 2014;89(10):1336-49.
33
34 228 17. Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and
35
36 229 multimorbidity in primary care practice: a PPRNet report. *J Am Board Fam Med.* 2013;26(5):518-24.
37
38 230 18. Health Canada. *Economic Burden of Illness in Canada.* Ottawa: Health Canada; 1998.
39
40 231 19. Wardle G, Wodchis WP, Laporte A, Anderson GM, Ross Baker G. The sensitivity of adverse
41
42 232 event cost estimates to diagnostic coding error. *Health Serv Res.* 2012;47(3 Pt 1):984-1007.
43
44 233 20. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative
45
46 234 drug claims in the Ontario Drug Benefit database. *Can J Clin Pharmacol.* 2003;10(2):67-71.
47
48 235 21. Scales DC, Guan J, Martin CM, Redelmeier DA. Administrative data accurately identified
49
50 236 intensive care unit admissions in Ontario. *JCE.* 2006;59(8):802-7.
51
52 237 22. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge
53
54 238 administrative data for patients admitted to cardiac care units in Ontario. *Am Heart J.* 2002;144(2):290-6.
55
56
57
58
59
60


- 1
2
3 239 23. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with
4
5 240 physician-diagnosed asthma in health administrative databases. *Can Respir J*. 2009;16(6):183-8.
6
7 241 24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals
8
9 242 with physician diagnosed COPD in health administrative databases. *COPD*. 2009;6(5):388-94.
10
11 243 25. Schultz SE, Rothwell DM, Chen Z, Tu K. Identifying cases of congestive heart failure from
12
13 244 administrative data: a validation study using primary care patient records. *Chronic Dis Inj Can*.
14
15 245 2013;33(3):160-6.
16
17 246 26. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and
18
19 247 incidence using a validated administrative data algorithm. *Diabetes Care*. 2002;25(3):512-6.
20
21 248 27. Guttmann A, Nakhla M, Henderson M, To T, Daneman D, Cauch-Dudek K, et al. Validation of a
22
23 249 health administrative data algorithm for assessing the epidemiology of diabetes in Canadian children.
24
25 250 *Pediatr Diabetes*. 2010;11(2):122-8.
26
27 251 28. Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative
28
29 252 databases in identifying patients with hypertension. *Open Med*. 2007;1(1):e18-26.
30
31 253 29. Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on Person-Level Costing
32
33 254 Using Administrative Databases in Ontario Health System Performance Research Network (HSPRN);
34
35 255 2013.
36
37 256 30. Ontario Ministry of Health and Long Term Care. Schedule of Benefits for Physician Services:
38
39 257 Consultations and Visits. 2014.
40
41 258 http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/a_consul.pdf. Accessed 30
42
43 259 October 2015.
44
45 260 31. Canadian Institute for Health Information. CCRS Technical Document—Ontario RUG Weighted
46
47 261 Patient Day Ottawa: Canadian Institute for Health Information; 2014.
48
49 262 32. Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the Canadian
50
51 263 Marginalization Index: a new tool for the study of inequality. *Can J Public Health*. 2012;103(8 Suppl
52
53 264 2):S12-6.
54
55
56
57
58
59
60

- 1
2
3 265 33. Matheson FI, White HL, Moineddin R, Dunn JR, Glazier RH. Neighbourhood chronic stress and
4
5 266 gender inequalities in hypertension among Canadian adults: a multilevel analysis. *J Epidemiol*
6
7 267 *Community Health*. 2010;64(8):705-13.
- 8
9
10 268 34. Nagl A, Witte J, Hodek JM, Greiner W. Relationship between multimorbidity and direct
11
12 269 healthcare costs in an advanced elderly population. Results of the PRISCUS trial. *Zeitschrift fur*
13
14 270 *Gerontologie und Geriatrie*. 2012;45(2):146-54.
- 15
16 271 35. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, et al. Multiple chronic
17
18 272 conditions: prevalence, health consequences, and implications for quality, care management, and costs. *J*
19
20 273 *Gen Intern Med*. 2007;22 Suppl 3:391-5.
- 21
22
23 274 36. Kralj B. Measuring Rurality - RIO2008_BASIC:Methodology and Results. 2008.
24
25 275 <https://www.oma.org/Resources/Documents/2008RIO-FullTechnicalPaper.pdf>. Accessed 30 October
26
27 276 2014.
- 28
29 277 37. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *JHE*.
30
31 278 2001;20(4):461-94.
- 32
33 279 38. Yoon J, Zulman D, Scott JY, Maciejewski ML. Costs associated with multimorbidity among VA
34
35 280 patients. *Med Care*. 2014;52 Suppl 3:S31-6.
- 36
37
38 281 39. Guthrie B, Saultz JW, Freeman GK, Haggerty JL. Continuity of care matters. *BMJ*.
39
40 282 2008;337:a867.
- 41
42 283 40. Kerr EA, Heisler M, Krein SL, Kabeto M, Langa KM, Weir D, et al. Beyond comorbidity counts:
43
44 284 how do comorbidity type and severity influence diabetes patients' treatment priorities and self-
45
46 285 management? *J Gen Intern Med*. 2007;22(12):1635-40.
- 47
48
49 286 41. Alemayehu B, Warner KE. The lifetime distribution of health care costs. *Health Serv Res*.
50
51 287 2004;39(3):627-42.
- 52
53 288 42. Macintyre S, Hunt K, Sweeting H. Gender differences in health: are things really as simple as
54
55 289 they seem? *Soc Sci Med*. 1996;42(4):617-24.
- 56
57
58
59
60

- 1
2
3 290 43. Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R. Age- and gender-related
4
5 291 prevalence of multimorbidity in primary care: the Swiss FIRE project. *BMC Fam Pract.* 2012;13:113.
6
7 292 44. Abad-Diez JM, Calderon-Larranaga A, Poncel-Falco A, Poblador-Plou B, Calderon-Meza JM,
8
9 293 Sicras-Mainar A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the
10
11 294 older population. *BMC Geriatr.* 2014;14:75.
12
13
14 295 45. Orueta JF, Nuno-Solinis R, Garcia-Alvarez A, Alonso-Moran E. Prevalence of multimorbidity
15
16 296 according to the deprivation level among the elderly in the Basque Country. *BMC Public Health.*
17
18 297 2013;13:918.
19
20
21 298 46. Williamson DL, Stewart MJ, Hayward K, Letourneau N, Makwarimba E, Masuda J, et al. Low-
22
23 299 income Canadians' experiences with health-related services: implications for health care reform. *Health*
24
25 300 *Policy.* 2006;76(1):106-21.
26
27 301 47. Crawford SM, Sauerzapf V, Haynes R, Forman D, Jones AP. Social and geographical factors
28
29 302 affecting access to treatment of colorectal cancer: a cancer registry study. *BMJ Open.* 2012;2(2):e000410.
30
31 303 48. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. *CMAJ.*
32
33 304 2016;188(3):182-8.
34
35
36 305 49. Canadian Institute for Health Information. Prescribed Drug Spending in Canada, 2013: A Focus
37
38 306 on Public Drug Programs. Ottawa: Canadian Institute for Health Information; 2014.
39
40 307 50. Islam MM, Yen L, Valderas JM, McRae IS. Out-of-pocket expenditure by Australian seniors
41
42 308 with chronic disease: the effect of specific diseases and morbidity clusters. *BMC Public Health.*
43
44 309 2014;14:1008.
45
46
47
48 310
49
50 311
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Distribution of total number of population and total health system costs in Ontario from April 1, 2009 to March 31, 2010



View only

Figure 2. Unadjusted mean total healthcare cost per capita for Ontario adults, by service type, number of conditions and age group from April 1, 2009 to March 31, 2010



Appendix 1. Proportions and mean number of chronic conditions by baseline characteristics,
April 1, 2009 to March 31, 2010

	N	Number of chronic conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
All cohort	6,639,089	52.2	24.2	12.3	6.1	5.2	1.88 (1.16)
Sex							
Female	3,541,644	49.2	25.3	13.4	6.6	5.5	1.94 (1.18)
Male	3,097,445	55.6	22.8	11.1	5.5	5.0	1.81 (1.14)
Age (years)							
0-19	809,782	89.8	9.3	0.8	0.1	0.01	1.11 (0.35)
20-34	908,634	77.2	18.8	3.4	0.5	0.1	1.27 (0.55)
35-44	875,680	66.5	24.4	7.0	1.7	0.5	1.45 (0.74)
45-64	2,410,603	47.0	29.9	14.4	5.7	3.0	1.88 (1.05)
65-74	836,640	25.3	29.3	22.3	12.7	10.4	2.53 (1.28)
70-74	383,237	21.8	28.2	23.2	14.2	12.6	2.68 (1.30)
75+	797,750	13.6	22.4	23.2	17.8	23.0	3.14 (1.36)
Income quintile							
Lowest	1,249,664	50.3	23.8	12.8	6.8	6.3	1.95 (1.21)
Middle-low	1,307,725	50.8	24.3	12.8	6.5	5.7	1.92 (1.18)
Middle	1,317,644	52.4	24.2	12.2	6.1	5.1	1.87 (1.15)
Middle-high	1,365,082	53.2	24.3	12.0	5.8	4.8	1.85 (1.13)
Highest	1,340,912	53.5	24.5	11.9	5.7	4.5	1.83 (1.12)
Rurality index							
Non-rural (< 40)	6,038,705	52.3	24.1	12.3	6.1	5.2	1.88 (1.56)
Rural (≥40)	514,225	48.9	25.0	13.3	6.8	5.9	1.96 (1.19)
Deprivation quintile							
Least deprived	1,654,445	55.0	24.0	11.4	5.3	4.3	1.80 (1.11)
Less deprived	1,504,855	52.6	24.4	12.2	5.9	4.9	1.86 (1.14)
Somewhat deprived	1,328,459	51.1	24.4	12.7	6.4	5.5	1.91 (1.17)
Very deprived	1,101,586	50.0	24.3	13.0	6.7	6.0	1.94 (1.20)
Most deprived	934,094	50.0	23.8	12.9	6.8	6.4	1.96 (1.21)

Supplementary Table 1. (Cont'd)

	N	Number of medical conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
Instability quintile							
Least unstable	1,715,922	56.6	24.0	11.0	4.9	3.5	1.75 (1.06)
Less unstable	1,365,580	53.2	24.4	12.1	5.8	4.6	1.84 (1.13)
Somewhat unstable	1,077,375	50.5	24.6	12.9	6.5	5.5	1.91 (1.17)
Very unstable	1,195,108	50.4	24.2	12.8	6.6	6.0	1.94 (1.20)
Most unstable	1,169,454	47.3	23.9	13.6	7.6	7.6	2.04 (1.26)
Dependency quintile							
Least dependent	1,400,521	59.3	23.3	10.0	4.3	3.1	1.69 (1.02)
Less dependent	1,456,755	55.5	24.1	11.3	5.2	4.0	1.78 (1.09)
Somewhat dependent	1,280,391	52.4	24.5	12.3	5.9	4.9	1.86 (1.14)
Very dependent	1,134,858	49.3	24.7	13.3	6.8	5.9	1.95 (1.19)
Most dependent	1,250,914	42.2	24.6	15.3	8.9	9.0	2.18 (1.31)
Ethnic concentration quintile							
Lowest	848,456	47.2	25.1	13.9	7.3	6.5	2.01 (1.22)
Middle-low	1,060,646	49.8	24.8	13.0	6.6	5.7	1.91 (1.19)
Middle	1,160,097	51.0	24.5	12.6	6.3	5.5	1.91 (1.17)
Middle-high	1,323,040	53.4	24.0	11.8	5.8	5.0	1.84 (1.14)
Highest	2,131,200	54.9	23.5	11.5	5.5	4.6	1.81 (1.12)
Primary care model							
Family health teams/ other primary care models	1,109,443	51.0	24.9	12.6	6.3	5.2	1.94 (1.28)
Family health networks /family health organizations	1,054,714	49.6	25.3	13.1	6.5	5.5	1.97 (1.30)
Community health centres/family health groups/non-rostered patients	4,474,932	53.1	23.7	12.0	6.0	5.2	1.90 (1.29)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	11-13
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11-13
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	Not report
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	Not report
		(c) Consider use of a flow diagram	Not report
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	Not report
Outcome data	15*	Report numbers of outcome events or summary measures	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16-23
		(b) Report category boundaries when continuous variables were categorized	16-23
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	19-23
Discussion			
Key results	18	Summarise key results with reference to study objectives	23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	26-27
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	26
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017264.R1
Article Type:	Research
Date Submitted by the Author:	22-Jun-2017
Complete List of Authors:	Thavorn, Kednapa; The Ottawa Hospital Research Institute; Institute for Clinical Evaluative Sciences, ICES @uOttawa Maxwell, Colleen; University of Waterloo, Schools of Pharmacy; Institute for Clinical Evaluative Sciences Gruneir, Andrea; University of Alberta, Department of Family Medicine; Institute for Clinical Evaluative Sciences Bronskill, Susan; Institute for Clinical and Evaluative Sciences ; University of Toronto, Canada Bai, YuQing; Institute for Clinical and Evaluative Sciences Koné Pefoyo, Anna; Lakehead University, Department of Health Sciences; University of Toronto, Dalla Lana School of Public Health Petrosyan, Yelena; University of Toronto, Institute of Health Policy, Management and Evaluation Wodchis, Walter; University of Toronto, Institute of Health Policy Management and Evaluation
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health economics
Keywords:	multimorbidity, health system cost, socio-demographic factors, population-based study, publicly funded healthcare system

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study

Kednapa Thavorn PhD^{1,2,3}, Colleen J. Maxwell PhD^{3,4}, Andrea Gruneir PhD^{3,5,6,7}, Susan E. Bronskill PhD^{3,5},
YuQing Bai MSc³, Anna J. Koné Pefoyo PhD^{8,9}, Yelena Petrosyan MD, MPH, PhD⁵,
Walter P. Wodchis PhD^{*3,5,10}

- 1 Ottawa Hospital Research Institute, The Ottawa Hospital;
2 School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa;
3 Institute for Clinical Evaluative Sciences;
4 Schools of Pharmacy, University of Waterloo;
5 Institute of Health Policy, Management and Evaluation, University of Toronto;
6 Women's College Research Institute, Women's College Hospital;
7 Department of Family Medicine, University of Alberta;
8 Department of Health Sciences, Lakehead University;
9 Dalla Lana School of Public Health, University of Toronto;
10. Toronto Rehabilitation Institute

Kednapa Thavorn, PhD
Ottawa Hospital Research Institute,
The Ottawa Hospital, 501 Smyth Road,
PO Box 201B, Ottawa, ON, Canada K1H 8L6
Email: kthavorn@ohri.ca

Colleen J. Maxwell, PhD
School of Pharmacy, University of Waterloo
10A Victoria St. S., PHR 4013
Kitchener, Ontario, Canada N2G 1C5
Email: colleen.maxwell@uwaterloo.ca

Andrea Gruneir PhD
Department of Family Medicine
Faculty of Medicine and Dentistry
6-40 University Terrace
Edmonton, Alberta Canada T6G 1C9
Email: gruneir@ualberta.ca

Susan E. Bronskill PhD
Institute for Clinical and Evaluative Sciences
G1 06, 2075 Bayview Avenue
Toronto, Ontario, Canada M4N 3M5
Email: susan.bronskill@ices.on.ca

1
2
3
4
5 YuQing Bai, MSc
6 Institute for Clinical and Evaluative Sciences (ICES UofT)
7 155 College Street, Suite 424
8 Toronto, Ontario, Canada M5T 3M6
9 **Email:** yuqing.bai@utoronto.ca
10

11
12 Anna J. Koné Pefoyo, PhD
13 Department of Health Sciences
14 Lakehead University
15 955 Oliver Rd
16 Thunder Bay, Ontario, P7B 5E1 Canada
17 **Email:** akonepe@lakeheadu.ca
18
19

20
21 Yelena Petrosyan, PhD (c)
22 Institute of Health Policy, Management and Evaluation
23 155 College Street
24 Toronto, Ontario, Canada M5T 3M6
25 **Email:** yelena.petrosyan@mail.utoronto.ca
26

27
28 Walter P. Wodchis, PhD, MAE, MA
29 Associate Professor
30 Institute of Health Policy, Management and Evaluation
31 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5 Canada
32 **Email:** walter.wodchis@utoronto.ca
33

34 ***Correspondence:**

35 **Address:**

36 Walter P. Wodchis, PhD, MAE, MA
37 Associate Professor
38 Institute of Health Policy, Management and Evaluation
39 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5
40 **Tel:** 416-946-7387
41 **Email:** walter.wodchis@utoronto.ca
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To estimate the attributable costs of multimorbidity and assess whether the association between the level of multimorbidity and health system costs varies by socio-demographic factors in young (<65) and older (≥ 65) adults living in Ontario, Canada.

Design: a population-based, retrospective cohort study

Setting: the province of Ontario, Canada

Participants: 6,639,089 Ontarians who were diagnosed with at least one of 16 selected medical conditions on April 1, 2009.

Main outcome measures: From the perspective of the publicly funded healthcare system, total annual healthcare costs were derived from linked provincial health administrative databases using a person-level costing method. We used generalized linear models to examine the association between the level of multimorbidity and healthcare costs and the extent to which socio-demographic variables modified this association.

Results: Attributable total costs of multimorbidity ranged from \$377 to \$2,073 for young individuals and \$1,026 to \$3,831 for older adults. The association between the degree of multimorbidity and healthcare costs was significantly modified by age ($p < 0.001$), sex ($p < 0.001$) and neighborhood income ($p < 0.001$) in both age groups. The positive association between healthcare costs and levels of multimorbidity was statistically stronger for older than younger adults. For individuals aged 65 years or younger, the increase in healthcare costs was more gradual in women than their male counterparts. For those aged 65 years or older, the increase in healthcare costs in women was significantly greater than for men. We also observed that the positive association between the level of multimorbidity and healthcare costs was significantly greater at higher levels of marginalization.

1
2
3
4
5 **Conclusion:** Socio-demographic factors are important effect modifiers of the relationship
6
7 between multimorbidity and healthcare costs; they should be considered in any discussion on the
8
9 implementation of healthcare policies and the organization of healthcare services aimed at
10
11 controlling healthcare costs associated with multimorbidity.
12
13

14
15
16 **KEYWORDS:** multimorbidity, health system costs, socio-demographic factors, population-
17
18 based study, publicly funded healthcare system
19

20
21 **Word Counts:** 295 (abstract), 4,000 (main text)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This population-based study was based on a large sample size and used the robust costing and generalized linear model regression techniques.
- The availability of linked and patient-level health administrative databases allows us to estimate the total health system costs associated with multimorbidity from all healthcare sectors.
- The use of health administrative databases can also minimize potential recall and non-response biases that are commonly found in survey data.
- The total healthcare costs reported in this study may be underestimated because they were derived based on selected 16 medical conditions. Moreover, it was not possible to measure some costs (e.g., deductibles and co-payments borne by supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated with caregiving) with our data.
- The study did not take into account particular clusters of medical conditions. It is possible that the relationship between multimorbidity and healthcare costs may vary according to the type and patterns of comorbid medical conditions.

BACKGROUND

Multimorbidity, the presence of the two or more co-existing conditions within a single person, is increasingly prevalent due to advances in life-extending medical treatments and increases in life expectancy. (1, 2) Internationally, the prevalence of multimorbidity has been shown to range from 17% in young adults (3) to 82% in older adults living in nursing homes. (4) In Canada, the prevalence of multimorbidity based on 16 selected conditions in Ontario rose from 17.4% in 2003 to 24.3% in 2009, and this increase was evident across all age groups.(5)

Higher levels of multimorbidity are associated with impaired physical functioning (6), poorer quality of life (7), more frequent use of health services, and higher risk of death. (8) In addition, individuals with multimorbidity may experience faster disease progression and require complex medical care services.(9) These individuals may be at a higher risk of receiving sub-optimal care (10), inappropriate prescriptions (11) and experiencing potentially preventable hospitalizations. (12)These adverse health outcomes can impose substantial burden on patients, family caregivers and the healthcare system.

The relationship between multimorbidity and healthcare costs is well-documented and has been shown to be curvilinear or exponential across jurisdictions. The average Medicare payments in the US ranged from \$1,154 among Part A and Part B beneficiaries with one chronic condition to \$13,973 among beneficiaries with at least four chronic conditions (a 12-fold difference). (12) Similarly, the mean total health system costs among older adults with multimorbidity in Switzerland was nearly six times higher than the those without multimorbidity. (13)

1
2
3
4
5 Despite an abundance of research describing the relationship between multimorbidity and
6 healthcare costs, existing studies have some important methodological and conceptual
7 limitations. Some previous studies (14, 15) used Ordinary Least Squares (OLS) regression
8 despite the fact that the positively skewed distribution of cost data often violates the normality
9 assumption of OLS. (16) Others attempted to overcome this problem by transforming cost data
10 to the logarithmic scale (13, 17); however, this transformation may still result in interpretation
11 problem as regression on transformed costs provides the prediction of a median instead of
12 arithmetic mean costs. (18) Importantly, the role of sociodemographic characteristics as effect
13 modifiers of the relationship between multimorbidity and healthcare costs remains poorly
14 described, although previous research has shown that the specific types of disease clusters vary
15 by age and sex (2, 19) and that multimorbidity is more prominent in selected visible minority and
16 low-socioeconomic status populations. (20)

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The objectives of this study were therefore to estimate the health system costs attributable to
multimorbidity using more rigorous and appropriate approach and assess the extent to which the
relationship between the level of multimorbidity and health system costs varies according to
sociodemographic characteristics.

METHODS

Study design and sample

This population-based, retrospective cohort study included all residents who lived in the
province of Ontario between April 1, 2001 and March 31, 2010, were enrolled in Ontario Health
Insurance Plan (OHIP), and were diagnosed with at least one of the following selected 16

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

medical conditions: acute myocardial infarction (AMI), arthritis, asthma, cancer, cardiac arrhythmia, chronic coronary syndrome, chronic obstructive pulmonary disorder (COPD), congestive heart failure, dementia, depression, diabetes, hypertension, osteoporosis, renal failure, rheumatoid arthritis and stroke. These conditions were selected because previous research and clinical experts agreed that they were highly prevalent and imposed substantial care and economic burden to Canada's healthcare system.(5, 21) We excluded people if they fell under the following criteria: had an invalid health card number, were older than 105 years old, died before the index date, or had no contact with the healthcare system in the last five years before the index date (excepting infants). We also excluded people with no contact with the healthcare system within the past five years as they might have left the province or experienced an unreported death.

Data Sources

We linked multiple provincial health administrative databases anonymously using unique encrypted identifiers. The Discharge Abstract Database provides data for all hospital discharges in Ontario, and the Ontario Health Insurance Plan (OHIP) claims database includes billing claims for all physician encounters. We used the Registered Persons Database to identify Ontarians who were eligible for health insurance coverage and derive age. The linked database was housed and secured at the Institute for Clinical Evaluative Sciences (ICES) under data security and privacy policies and procedures approved by the Information and Privacy Commissioner of Ontario. This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

1
2
3
4 Each medical condition was defined using diagnostic algorithms and consultation codes that
5
6 have been validated or used in previous studies. We defined six conditions (AMI, asthma,
7
8 chronic heart failure, COPD, diabetes, and hypertension) based on validated population derived
9
10 registries held at ICES. (22-28) These conditions were all defined based on one diagnosis
11
12 recorded in acute care or two diagnoses recorded in ambulatory care (physician) records within a
13
14 two-year period (i.e. between 2007/8 and 2008/09), except for AMI which was defined using
15
16 acute care records in 2008/09. A similar approach was adopted to define the remaining medical
17
18 conditions including arthritis, cancer, cardiac arrhythmia, chronic coronary syndrome, dementia,
19
20 depression, osteoporosis, renal failure, rheumatoid arthritis and stroke. List of diagnostic codes
21
22 used to define medical conditions are shown in Appendix 1.
23
24
25
26
27
28
29

30 **Measures**

31 *Healthcare costs*

32
33 Healthcare costs were estimated from a perspective of the publicly funded healthcare system;
34
35 accordingly, only direct costs borne to the Ontario Ministry of Health and Long-Term Care were
36
37 considered. In Ontario, medically necessary hospital and physician services are paid for by the
38
39 publicly-financed health insurance plan. Public coverage for prescription drugs is primarily
40
41 limited to residents aged 65 years and over, social assistance recipients as well as those with high
42
43 prescription drug costs compared to their net household income.
44
45
46
47
48
49

50
51 We identified, measured and valued direct healthcare costs by applying a person-level costing
52
53 technique that was developed and validated based on the Ontario health administrative data. (29)

54
55 We calculated the costs of inpatient hospitalizations, emergency department visits, same day
56
57
58
59
60

1
2
3
4
5 surgeries, and inpatient rehabilitation by multiplying the weighted volume of services by the
6
7 average provincial costs per weighted case. We obtained the costs of fee-for-service physician
8
9 and outpatient diagnostic or laboratory services through OHIP fee approved as outlined in the
10
11 Ontario Health Insurance Schedule of Benefits and Fees. (30) We calculated non-fee-for-service
12
13 physician payments by applying applicable capitation payments or the median amount
14
15 reimbursed for the same service code for the specific fiscal year. (29) Costs for high-cost medical
16
17 device equipment were estimated from the amount reimbursed to patients recorded in the
18
19 Assistive Devices Program database. Complex continuing care and inpatient psychiatric costs
20
21 were based on case mix, number of days in care, and Resource Utilization Groups. (31) Patient
22
23 costs for long-term care were estimated based on a fixed per diem based on prevailing
24
25 government payment rates, and costs for home care were estimated using average cost per hour.
26
27 We used pharmacy payments recorded in the Ontario Drug Benefit database to capture
28
29 prescription medication costs for individuals eligible for public coverage. Annual total direct
30
31 healthcare costs were the sum of costs across healthcare sectors for each patient for a one-year
32
33 period, i.e. from April 2009 to March 2010.
34
35
36
37
38
39
40
41

42 We categorized healthcare costs into five components: physician, hospital, drug, continuing care
43
44 and other healthcare delivery costs. Physician costs included professional fees paid by the
45
46 provincial insurance plan directly to physicians in private practice. Hospital costs included
47
48 amounts paid to healthcare institutions, including those providing acute care, extended and
49
50 chronic care, rehabilitation and convalescent care, psychiatric care, as well as drugs dispensed in
51
52 hospitals. Drug costs consist of the costs for prescriptions dispensed at outpatient pharmacies to
53
54 individuals eligible for provincial coverage, while continuing care costs included expenditure on
55
56
57
58
59
60

1
2
3
4 home care and residential long-term (nursing-home) care. The other healthcare delivery costs
5
6 category represented expenditures on an assistive device program that subsidizes high-cost
7
8 equipment, such as wheel chairs, walkers, continuous positive airway pressure devices and
9
10 insulin pumps, for patients with physical disabilities. All costs were expressed in 2009 Canadian
11
12 Dollars.
13
14

15 16 17 18 19 *Independent variables*

20
21 Multimorbidity was defined as the occurrence of two or more chronic diseases among the 16
22
23 selected conditions within a single individual and was categorized into five groups. A categorical
24
25 variable was created to capture those with no multimorbidity (single disease only), two, three,
26
27 four and five or more multimorbid conditions. Socio-demographic variables consisted of age,
28
29 sex, income and level of marginalization. As prescription drug costs among Ontarians aged less
30
31 than 65 years are primarily covered by private drug plans, we ran separate regressions for
32
33 younger (<65 years) and older (65+ years) cohorts. We also included a continuous variable of
34
35 age in the models. Income level was categorized to five quintiles, with the lowest quintile
36
37 reflecting the lower income level. We used the Ontario Marginalization Index, a validated
38
39 census- and geographically-based index, as a proxy for individual-level sociodemographic
40
41 factors. (32) The index consisted of four dimensions of marginalization: material deprivation;
42
43 residential instability; ethnic concentration; and dependency. Lower scores on each dimension
44
45 represent areas that are the least marginalized and higher scores represent areas that are the most
46
47 marginalized. This index has been shown to be associated with several health outcomes. (33)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 We also controlled for other factors, such as type of primary care model and geographic location,
6
7 that might confound the impact of multimorbidity on healthcare costs. Selection of such factors
8
9 was guided by previous healthcare costs studies (12, 34, 35) and was subject to their availability
10
11 in Ontario administrative databases. The primary care model was categorized into three groups:
12
13 group-based teams with capitation/salary and team-based payment (family health teams/other
14
15 group models); capitation or blended payment models (family health networks/family health
16
17 organizations); or primarily fee for service (family health groups and non-rostered patients). We
18
19 assigned a geographic location to each individual using the Rurality Index for Ontario (36),
20
21 whereby a value greater than 40 was considered to be a designated rural area.
22
23
24
25
26
27

28 **Analysis**

29
30 Annual healthcare costs per capita were described by health service sector, age group (<65 vs.
31
32 ≥ 65 years), the degree of multimorbidity and each of the independent factors, such as sex, age
33
34 group, and level of marginalization. Multivariate regression analyses were used to assess the
35
36 incremental costs of interest in this study. To identify the regression model that fits best with the
37
38 cost data, we followed the steps suggested by Manning and Mullahy. (37) We first ran ordinary
39
40 least-squares regressions (OLS) of the logarithmic transformation of cost data on the number of
41
42 medical conditions and other confounding factors. However, the OLS regression was deemed
43
44 inappropriate because the residuals were not normally distributed. The generalized linear model
45
46 (GLM) with a log-link function and a gamma distribution was chosen because a modified Park
47
48 test suggested that the variance was proportional to the conditional mean. The GLM allows us to
49
50 estimate mean healthcare costs without the need for retransformation.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Attributable costs due to multimorbidity were estimated by subtracting the mean predicted cost of one medical condition from two conditions, two from three conditions, three from four conditions, and four from at least five conditions, respectively. To investigate whether the relationship between the level of multimorbidity and healthcare costs was moderated by socio-demographic factors, we added two-way interaction terms between the level of multimorbidity and each sociodemographic factor, including sex, age, income level, deprivation quintile, instability quintile, dependency quintile and ethnic concentration quintile. The significance of interaction terms was assessed by comparing the likelihood ratio of the full model with all interaction terms to the model without interaction terms using the likelihood ratio test.

The model performance, including goodness of fit and specifications, was examined by checking the scaled deviance, Pearson's chi-square statistics and residual plots, respectively. All analyses were performed using SAS statistical software for UNIX (version 9.3; SAS Institute, Cary, North Carolina).

RESULTS

We identified a cohort of 6,639,089 individuals living with at least one of the selected 16 medical conditions in Ontario in 2009 (see Appendix 2 for baseline characteristics). Our cohort represents about 50% of the total population in the province of Ontario in 2009. Close to half of the study cohort (48%) had at least two selected medical conditions, and this prevalence was found to increase with age. The majority of the study cohort was younger than 65 years of age (75%) and just over half was female (53%). Nearly all individuals (91%) resided in non-rural

1
2
3
4 areas, and about one-third (33%) lived in neighborhoods with a high proportion of diverse ethnic
5
6 groups.
7
8

9
10
11 The total annual healthcare cost estimated for the study cohort was \$26.5 billion. As shown in
12
13 Figure 1, individuals living with at least two selected medical conditions represented 24.4% of
14
15 total population of Ontario (~13 million) but accounted for approximately two-thirds (67.9%) of
16
17 total allocatable healthcare costs in 2009/10. By contrast, individuals without multimorbidity
18
19 who accounted for 76% of the total population were responsible for only 32.1% of total
20
21 allocatable healthcare costs. On average, annual total costs per capita amounted to \$2,217 in
22
23 individuals younger than 65 years and \$9,398 in those aged 65 years or older.
24
25
26
27

28 [Figure 1]

29
30 Table 1 shows the annual total costs per capita by baseline characteristics for young and older
31
32 adults. For both age groups, per capita total healthcare costs were higher in women than men.
33
34 The average healthcare costs increased with older age. The greater levels of marginalization
35
36 were associated with higher healthcare costs in both age groups. Mean total healthcare costs
37
38 were the highest among individuals living in the most deprived and most unstable areas as well
39
40 as those who were highly dependent. However, mean total costs decreased with higher income
41
42 level.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Annual per capita healthcare costs by baseline characteristics and age group, April 1, 2009 to March 31, 2010

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
All cohort	5,004,699	2,217 (9630)	502 (193-1317)	1,634,390	9,398 (19,796)	2,982 (1,448-7,178)
Sex						
Female	2,618,591	2,311 (9,044)	624 (248– 1,546)	923,053	9,526.96 (19,245)	2,991.97 (1,461-7,344)
Male	2,386,108	2,113 (10,233)	378.67 (132– 1,058)	711,337	9,230.31 (20,488)	2,968.13 (1,431-6,982)
Age group (years)						
<20	809,782	997 (6,420)	257 (103-600)			
20 - 44	1,784,314	1,835 (7,997)	440 (155-1,171)			
45 – 64	3,247,243	2,910 (11,414)	684 (291-1,725)			
65 - 74				1,219,877	6,424 (16,464)	2,363 (1,173-4,757)
75+				797,750	12,517 (22,351)	3,964 (1,884-12,277)
Income quintile						
Lowest	935,048	2,822 (11,333)	580 (206-1699)	314,616	10,646 (21,501)	3,325 (1,596-8,667)
Middle-low	970,797	2,360 (10,276)	521 (199-1,380)	336,928	9,529 (20,218)	3,053 (1,501-7,296)
Middle	999,087	2,107 (9,146)	498 (195-1,268)	318,557	9,319 (19,552)	2,992 (1,470-7,114)
Middle-high	1,042,284	2,008 (8,899)	487 (195-1,226)	322,798	9,120 (19,279)	2,916 (1,426-6,873)
Highest	1,009,890	1,903 (8,391)	475 (192-1,180)	331,022	8,549 (18,309)	2,747 (1,351-6,352)
Rurality index						
Non-rural	4,579,691	2,206 (9,605)	509 (197-1,320)	1,459,014	9,448 (19,998)	3,005 (1,470-7,161)
Rural	356,361	2,522 (10,112)	501 (197-1,441)	157,864	9,333 (18,303)	2,918 (1,400-7,798)
Deprivation quintile						

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
Least deprived	1,282,898	1,894.17 (8,596.59)	476 (193-1,170)	371,547	9,167 (19,628)	2,823 (1,380-6,709)
Less deprived	1,136,731	2,015 (8,810)	489 (196-1,231)	368,124	8,935 (18,928)	2,898 (1,423-6,759)
Somewhat deprived	982,133	2,193 (9,240)	504 (196-1,311)	346,326	9,165 (19,300)	2,978 (1,463-7,030)
Very deprived	808,152	2,438 (10,281)	511 (200-1,443)	293,434	9,541 (19,951)	3,100 (1,520-7,467)
Most deprived	705,593	2,941 (11,861)	600 (210-1,79)	228,501	10,517 (21,250)	3,326 (1,599-8,570)
Instability quintile						
Least dependent	1,211,734	2,007 (8,674)	489 (188-1,250)	188,787	8,149 (19,413)	2,713 (1,307-5,882)
Less dependent	1,179,936	2,078 (9,134)	500 (195-1,275)	276,819	8,359 (18,652)	2,777 (1,353-6,167)
Somewhat dependent	976,538	2,230 (9,793)	506 (198-1,320)	303,853	8,717 (19,018)	2,849 (1,401-6,548)
Very dependent	808,196	2,349 (9,954)	515 (201-1,375)	326,662	9,068 (19,195)	2,944 (1,458-6,958)
Most dependent	739,103	2,650 (10,947)	550 (213-1,507)	511,811	10,961 (20,953)	3,381 (1,636-9,336)
Ethnic concentration quintile						
Lowest	564,476	2,398 (9,766)	500 (200-1,370)	283,980	9,309 (18,529)	2,983 (1,463-7,533)
Middle-low	756,120	2,288 (9,552)	491 (196-1,317)	304,526	9,170 (18,773)	2,969 (1,458-7,283)
Middle	854,573	2,280 (9,780)	497 (196-1,317)	305,524	9,540 (19,678)	3,011 (1,478-7,419)
Middle-high	1,028,876	2,190 (9,565)	502 (195-1,309)	294,164	9,600 (20,240)	3,012 (1,473-7,266)
Highest	1,711,462	2,124 (9,468)	528 (199-1,331)	419,738	9,288 (20,751)	2,981 (1,441-6,694)

Note: SD, standard deviation; IQR, interquartile range

Figure 2 illustrates the distribution of total cost per capita by type of services. Among individuals younger than 65 years of age, hospitalization was the primary cost driver and responsible for 47% of total healthcare costs, followed by physician costs (32%), drug costs (10%), and

1
2
3
4 continuing care costs (6%). For older adults, hospital costs remained the largest cost component
5
6 (41%), followed by continuing care costs (23%), drug costs (19%) and physician costs (15%).
7
8

9
10 Figure 2 also reveals that unadjusted mean total costs increased with additional numbers of
11
12 medical conditions, ranging from \$1,352 in individuals younger than 65 years of age without
13
14 multimorbidity to \$13,105 in those living with five or more medical conditions, corresponding to
15
16 a 10-fold increase. On the other hand, while \$4,185 was spent on older adults without
17
18 multimorbidity, spending increased by about 5-fold to \$19,196 in those living with five or more
19
20 medical conditions.
21
22

23 [Figure 2]
24

25
26 Table 2 shows adjusted attributable costs of multimorbidity after controlling for other factors.
27
28 Among individuals younger than 65 years, the attributable total cost was \$377 in those living
29
30 with two medical conditions and \$2,073 in those living with at least 5 medical conditions,
31
32 corresponding to a six times higher attributable cost. Similarly, attributable total costs in older
33
34 adults also rose with increasing number of medical conditions, ranging from \$1,026 in those with
35
36 two medical conditions to \$3,831 in those with five or more. The magnitude of an incremental
37
38 cost depended on a reference category. Specifically, one additional medical condition to young
39
40 adults without multimorbidity led to an attributable cost of \$377, while for young adults who
41
42 already had three medical conditions, one more health condition incurred additional \$798. These
43
44 incremental costs were even greater in older adults, whereby an incremental cost rose from
45
46 \$1,026 (1 vs. 2 conditions) to \$1,652 (3 vs. 4 conditions). Similar patterns were observed for
47
48 subdivided healthcare costs, which varied across age groups [Table 2]. An additional medical
49
50 condition caused 1- to 3-fold increase in the costs of each health sector except for hospital
51
52
53
54
55
56
57
58
59
60

1
2
3
4 whereby incremental costs increased steady from \$185 to \$802 in the younger cohort and from
5
6
7 \$232 to \$1,060 in the older adult cohort.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Adjusted incremental total healthcare costs by the degree of multimorbidity and age group*, April 1, 2009 to March 31, 2010

conditions	< 65 years (N=5,004,699)						≥ 65 years (N=1,634,390)					
	total (\$)	physician (\$)	hospital (\$)	drug (\$)	continuing care (\$)	Others (\$)	total (\$)	physician (\$)	hospital (\$)	drug (\$)	continuing care (\$)	others (\$)
2 vs. 1	376.50	200.26	185.12	232.37	288.71	23.96	1,025.76	166.48	231.60	350.29	254.14	23.54
3 vs. 2	534.34	238.28	207.22	252.84	207.83	23.81	1,279.96	201.20	247.76	403.56	314.91	28.51
4 vs. 3	798.03	286.29	264.75	316.43	234.58	24.67	1,651.92	227.04	353.60	429.01	367.45	33.17
≥5 vs. 4	2,072.57	515.80	801.64	666.13	486.58	37.64	3,831.40	400.57	1060.00	673.89	732.19	63.76

*adjusted for sex, age, income quintile, primary care model, rurality index, deprivation quintile, instability quintile, dependency quintile, and ethnic concentration quintile

1
2
3 We also found that the association between number of medical conditions and healthcare costs
4 was significantly modified by age and sex for both young and older adults [Table 3]. The
5
6 positive association between healthcare costs and levels of multimorbidity was significantly
7
8 stronger for older than younger adults. For individuals aged 65 years or younger, the increase in
9
10 healthcare costs was more gradual in women than their male counterparts. For those aged 65
11
12 years or older, the increase in healthcare costs in women was significantly greater than for men.
13
14
15
16
17
18
19

20 For both age groups, we observed small interaction effects between the number of medical
21
22 conditions and other socio-demographic factors. The rise in healthcare costs with greater level of
23
24 multimorbidity was less pronounced among individuals with high income level. The association
25
26 between the level of multimorbidity and healthcare costs was significantly modified by the level
27
28 of deprivation, instability, dependency and ethnic concentration. The positive association
29
30 between the level of multimorbidity and healthcare costs was stronger among individuals living
31
32 in more deprived, unstable, dependent or diverse ethnic groups than those living in less deprived,
33
34 stable, dependent or diverse ethnic concentration areas. We did not observe a significant
35
36 interaction between the number of medical conditions and the level of dependency in the older
37
38 adult cohort.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Generalized linear models results for total healthcare costs[^]

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
Intercept	1.6844***	0.0007	1.6049***	0.0034
Age	0.0023***	0.0001	0.0053***	0.0001
Sex				
Male	reference		reference	
Female	0.0628***	0.0002	-0.0023***	0.0006
Number of medical conditions				
1 condition	reference		reference	
2 conditions	0.1092***	0.0017	0.1068***	0.0044
3 conditions	0.2189***	0.0027	0.1860***	0.0045
4 conditions	0.3312***	0.0050	0.2563***	0.0049
≥5 conditions	0.4203***	0.0080	0.3772***	0.0048
Income quintile				
Lowest	reference		reference	
Middle-low	-0.0043***	0.0005	-0.0019*	0.0010
Middle	-0.0045***	0.0005	0.00014	0.0012
Middle-high	-0.0044***	0.0006	0.0001	0.0012
Highest	-0.0080***	0.0006	-0.0045***	0.0013
Deprivation quintile				
Least deprived	reference		reference	
Less deprived	-0.0006*	0.0004	-0.0014***	0.0008
Somewhat deprived	-0.0008*	0.0004	-0.0020**	0.0009
Very deprived	0.0022***	0.0005	-0.0009	0.0011
Most deprived	0.0135***	0.0006	0.0044***	0.0013
Instability quintile				
Least unstable	reference		reference	
Less unstable	0.0039***	0.0005	-0.0019**	0.0009
Somewhat unstable	0.0073***	0.0005	-0.0008	0.0009
Very unstable	0.0122***	0.0005	0.0031***	0.0009
Most unstable	0.0247***	0.0005	0.0087***	0.0010
Ethnic concentration quintile				
Lowest	reference		reference	
Middle-low	0.0002	0.0004	-0.0005	0.0009
Middle	0.0018***	0.0004	0.0022	0.0009
Middle-high	0.0047***	0.0004	-0.0007	0.0010
Highest	0.0066***	0.0004	-0.0043***	0.0009
Dependency quintile				
Least dependent	reference		reference	
Less dependent	0.0004	0.0004	0.0012**	0.0005
Somewhat dependent	0.0001	0.0004	0.0027***	0.0005
Very dependent	0.0009**	0.0004	0.0030***	0.0005

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
Most dependent	0.0020***	0.0005	0.0100***	0.0005
Number of medical conditions * sex				
1 condition* Male	reference		reference	
2 conditions * Female	-0.0171***	0.0016	-0.0029***	0.0007
3 conditions * Female	-0.0396***	0.0011	-0.0022***	0.0008
4 conditions * Female	-0.0549***	0.0007	0.0001	0.0008
≥5 conditions * Female	-0.0659***	0.0005	0.0030***	0.0008
Number of medical conditions * age				
1 condition * age	reference		reference	
2 conditions * age	-0.0007***	0.0016	-0.0006***	0.0001
3 conditions * age	-0.0014***	0.0011	-0.0010***	0.0001
4 conditions * age	-0.0022***	0.0007	-0.0014***	0.0001
≥5 conditions * age	-0.0023***	0.0005	-0.0023***	0.0001
Number of medical conditions * income quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0016*	0.0009	-0.0025*	0.0013
3 conditions * middle-low	-0.0011	0.0013	-0.0037**	0.0014
4 conditions* middle-low	-0.0043**	0.0020	-0.0043**	0.0015
≥5 conditions* middle-low	-0.0031	0.0027	-0.0046**	0.0014
2 conditions*middle	-0.0020**	0.0010	-0.0032**	0.0015
3 conditions * middle	-0.0030**	0.0014	-0.0051**	0.0015
4 conditions* middle	-0.0053**	0.0023	-0.0055**	0.0017
≥5 conditions* middle	-0.0028	0.0031	-0.0072***	0.0016
2 conditions*middle-high	-0.0024**	0.0011	-0.0031*	0.0016
3 conditions * middle-high	-0.0032**	0.0016	-0.0052**	0.0016
4 conditions* middle-high	-0.0067**	0.0025	-0.0081***	0.0018
≥5 conditions* middle-high	-0.0093**	0.0034	-0.0070***	0.0018
2 conditions*highest	-0.0015	0.0011	-0.0036**	0.0017
3 conditions * highest	-0.0031*	0.0017	-0.0063***	0.0018
4 conditions* highest	-0.0096***	0.0027	-0.0088***	0.0019
5 conditions* highest	-0.0099**	0.0038	-0.0095***	0.0019
Number of medical conditions * deprivation quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	0.0024***	0.0007	-0.0001	0.0011
3 conditions * middle-low	0.0038 ***	0.0010	-0.0015	0.0011
4 conditions* middle-low	0.0027	0.0017	-0.0016	0.0013
≥5 conditions* middle-low	0.0060**	0.0026	-0.0029**	0.0012
2 conditions*middle	0.0047***	0.0007	-0.0002	0.0012
3 conditions * middle	0.0067***	0.0010	-0.0018	0.0013
4 conditions* middle	0.0062***	0.0017	-0.0045**	0.0014
≥5 conditions* middle	0.0109***	0.0026	-0.0042**	0.0014
2 conditions*middle-high	0.0057***	0.0009	-0.0012	0.0014

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
3 conditions * middle-high	0.0071***	0.0014	-0.0031**	0.0015
4 conditions* middle-high	0.0074***	0.0022	-0.0051**	0.0016
≥5 conditions* middle-high	0.0111***	0.0032	-0.0079***	0.0016
2 conditions*highest	0.0073***	0.0011	-0.0028	0.0017
3 conditions *highest	0.0108***	0.0016	-0.0052**	0.0018
4 conditions* highest	0.0114***	0.0026	-0.0089***	0.0019
≥5 conditions* highest	0.0119***	0.0036	-0.0098***	0.0019
Number of medical conditions * instability				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0012**	0.0007	0.0009	0.0011
3 conditions * middle-low	-0.0007	0.0010	0.0020	0.0012
4 conditions* middle-low	-0.0016	0.0017	0.0010	0.0013
≥5 conditions* middle-low	-0.0013	0.0026	0.0022	0.0014
2 conditions*middle	-0.0017**	0.0008	0.0037**	0.0014
3 conditions * middle	-0.0012	0.0012	0.0010	0.0013
4 conditions* middle	-0.0002	0.0019	0.0022	0.0014
≥5 conditions* middle	0.0025	0.0027	0.0037**	0.0014
2 conditions*middle-high	-0.0003	0.0009	0.0022*	0.0012
3 conditions * middle-high	0.0006	0.0012	0.0019	0.0013
4 conditions* middle-high	0.0011	0.0019	0.0033**	0.0014
≥5 conditions* middle-high	0.0075***	0.0027	0.0048***	0.0014
2 conditions*highest	0.0037***	0.0012	-0.0027**	0.0013
3 conditions *highest	0.0095***	0.0012	-0.0026**	0.0013
4 conditions* highest	0.0113***	0.0020	-0.0035**	0.0014
≥5 conditions* highest	0.0206***	0.0028	-0.0019	0.0014
Number of medical conditions * ethnic concentration				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0006	0.0009	0.0011	0.0012
3 conditions * middle-low	-0.0007	0.0013	0.0022*	0.0012
Number of medical conditions * ethnic concentration				
4 conditions* middle-low	-0.0020	0.0021	0.0012	0.0014
≥5 conditions* middle-low	0.0018	0.0029	0.0012	0.0013
2 conditions*middle	0.0004	0.0009	0.0006	0.0012
3 conditions * middle	-0.0006	0.0013	0.0003	0.0012
4 conditions* middle	-0.0034	0.0021	-0.0012	0.0014
≥5 conditions* middle	0.0016	0.0030	0.0004	0.0013
2 conditions*middle-high	0.0002	0.0009	0.0015	0.0012
3 conditions * middle-high	-0.0013	0.0014	0.0021*	0.0013
4 conditions* middle-high	-0.0056**	0.0022	0.0006	0.0014
≥5 conditions* middle-high	-0.0056*	0.0030	0.0035**	0.0014
2 conditions*highest	-0.0008	0.0012	0.0043***	0.0012
3 conditions *highest	-0.0021	0.0013	0.0047***	0.0013

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
4 conditions* highest	-0.0081***	0.0021	0.0044***	0.0013
≥5 conditions* highest	-0.0070**	0.0030	0.0093***	0.0013
Number of medical conditions * dependency quintile[#]				
1 condition* lowest	reference		reference	
2 conditions* middle-low	0.0016**	0.0007		
3 conditions * middle-low	0.0018**	0.0010		
4 conditions* middle-low	0.0004	0.0017		
≥5 conditions* middle-low	-0.0028	0.0026		
2 conditions* middle	0.0015**	0.0001		
3 conditions * middle	0.0030***	0.0011		
4 conditions* middle	0.0036**	0.0018		
≥5 conditions* middle	0.0008	0.0025		
2 conditions* middle-high	0.0017**	0.0008		
3 conditions * middle-high	0.0029**	0.0012		
4 conditions* middle-high	0.0028	0.0019		
≥5 conditions* middle-high	0.0014	0.0027		
2 conditions* highest	0.0018**	0.0009		
3 conditions * highest	0.0032**	0.0013		
4 conditions* highest	0.0041**	0.0020		
≥5 conditions* highest	0.0038	0.0028		
AIC	15,672,974		5,058,276	
BIC	15,674,535		5,059,515	

^ adjusted for primary care models and rurality index; *** P < 0.001, ** P < 0.05, * p < 0.10; se indicates standard error; # interaction between the number of medical conditions and dependency quintile was not statistically significant and therefore excluded from a final model.

DISCUSSION

Individuals living with multimorbidity accounted for 79% of total healthcare costs incurred by our study cohort and 68% of total allocatable healthcare costs in Ontario in 2009. Although there is a growing body of literature documenting the economic burden of multimorbidity in other jurisdictions (12, 13, 38), the current study lends further evidence that a relatively small portion of the multimorbid population was responsible for a disproportionately high percentage of total healthcare costs. We observed this disproportionate relationship in both young (<65) and (65+)

1
2
3 older cohorts, suggesting that any approaches to containing healthcare costs of multimorbidity
4
5 should be implemented across all age groups.
6
7
8
9

10 Our study demonstrated that healthcare costs increased significantly with higher levels of
11 multimorbidity. This positive association exists even after the adjustment for confounding factors
12 and a skewed distribution of cost data using the generalized linear model with a log link function
13 and a gamma distribution. The exponential relationship between multimorbidity and incremental
14 healthcare costs shown in this study suggests that the financial burden of multimorbidity to the
15 healthcare system is not simply equal to the sum of costs incurred by each individual condition.
16 This non-linearity reflects the complex association of the degree of multimorbidity, the type of
17 disease clusters and healthcare costs. It is likely that patients with multimorbidity might
18 experience worse health outcomes and require more complex clinical management.(9) They are
19 also vulnerable to receiving redundant diagnostic tests (12), suboptimal transition of care and
20 inappropriate prescriptions. (11) This explanation is plausible as current treatment guidelines are
21 mainly focused on individual disease management.(10) Thus, as the number of healthcare
22 providers involved in the patient's care increases, information sharing and coordinating care
23 across healthcare providers may pose a challenge. (39) Moreover, an increasing number of
24 comorbid conditions may compromise patients' ability to self-manage their diseases.(40) The
25 high healthcare spending on multimorbidity found in our study underscores the need for ensuring
26 continuity and coordination of care in this population.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51
52
53 More importantly, our study contributes to the understanding of the association between the
54 degree of multimorbidity and healthcare costs. We observed that each unit increase in age
55
56
57
58
59
60

1
2
3 amplified the rise in healthcare costs associated with an increasing number of medical
4
5 conditions. The observed interaction effect may partly due to patterns in the healthcare use
6
7 among an older population. There is generally a pattern of poly-pharmacy and use of continuing
8
9 care services that are very costly. Additionally, we found that the positive association between
10
11 healthcare costs and levels of multimorbidity was stronger in men than women among
12
13 individuals younger than 65 years. This sex difference might relate to different disease clusters
14
15 whereby men within this age group often experience life-threatening and more serious illnesses
16
17 than women.(41, 42) For those older than 65 years, the increase in healthcare costs with the
18
19 greater level of multimorbidity were significantly higher in women than men. This sex difference
20
21 could be partially explained by longer life expectancy and greater risk of multimorbidity in older
22
23 women than men (20, 43), which may cause older women to be more dependent on formal (paid)
24
25 healthcare services and other informal (unpaid) caregivers.
26
27
28
29
30
31
32
33

34 We observed small interaction effects of neighborhood-level socioeconomic characteristics on
35
36 the association between the number of medical conditions and healthcare costs. Living in lower
37
38 income and marginalized area, i.e. greater levels of instability, dependency or ethnic
39
40 concentration, accelerated the increase in health system costs with the greater level of
41
42 multimorbidity. This might reflect a higher risk of experiencing more complex multimorbid
43
44 conditions among individuals living in disadvantaged neighborhood (44) which led to greater
45
46 demand and utilization of healthcare. Another possible reason is that individuals living in more
47
48 deprived area may face barriers in accessing health services (45) and have delayed access to
49
50 preventive healthcare interventions or treatments (46), thereby having a higher risk of worse
51
52 health outcomes and high healthcare costs. The effects of socioeconomic factors reported in this
53
54
55
56
57
58
59
60

1
2
3 study should be interpreted with caution as they were derived based on neighborhood. Although
4
5 the interaction terms between socioeconomic factors and levels of multimorbidity were
6
7 statistically significant, most of estimated effect sizes were very small and might be a result of a
8
9 large sample size used in this study.
10
11

12 13 14 15 **Strengths and limitations**

16
17 This population-based study was based on a large sample size and used the robust costing and
18
19 generalized linear model regression techniques. The availability of linked and patient-level
20
21 health administrative databases allows us to estimate the total health system costs associated with
22
23 multimorbidity from all healthcare sectors. The use of health administrative databases can also
24
25 minimize potential recall and non-response biases that are commonly found in survey data.
26
27

28
29 However, the results of this study should be interpreted in light of the following limitations.
30
31

32
33 First, we estimated healthcare costs based on selected 16 medical conditions. The selection of a
34
35 limited number of medical conditions is likely to underestimate the overall healthcare costs of
36
37 multimorbidity. However, total cost estimates reported in our study were comprehensive because
38
39 they amounted to 86% of total allocatable government expenditures in Ontario in 2009.(47)
40
41

42
43 Second, due to a paucity of data, some costs (e.g., deductibles and co-payments borne by
44
45 supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated
46
47 with caregiving) were excluded from the analysis. In addition, this study could not capture the
48
49 costs of medications covered by private sectors, including private insurers and out of pocket
50
51 expenses which represent the largest component of total prescription drug costs of Canadians
52
53
54
55
56
57
58
59
60

1
2
3 who are younger than 65 years of age. (48) For this reason, findings from this study may not be
4
5 generalizable to other jurisdictions with different healthcare systems.
6
7

8
9
10 Third, this study did not take into account the clusters of medical conditions. It is possible that
11
12 the relationship between multimorbidity and healthcare costs may vary according to the type and
13
14 patterns of comorbid medical conditions. We chose to use disease counts because there is no
15
16 standard or guidance on how to measure and define multimorbidity and the choice of measure
17
18 would be subject to data availability and the outcome of interest. (49, 50) A previous study
19
20 conducted by our team (5) has shown that there were no common clustering of diseases among
21
22 individuals living with multimorbidity. The number of disease clusters required to include 80%
23
24 of the study population increased from 14 (among individuals with two conditions) to 2744
25
26 clusters of conditions (among individuals with 5 or more conditions). Moreover, a previous
27
28 systematic review showed that 132 multimorbid definitions with 1,631 criteria were used to
29
30 define multimorbidity in the published literature. (51) Our decision to use disease counts is also
31
32 supported by a study by Islam et al (52) indicating that the total number of chronic conditions
33
34 were more predictive for out-of-pocket healthcare costs and high cost users than the clusters,
35
36 dominant groups or dominant pairs.
37
38
39
40
41
42
43
44

45 **CONCLUSION**

46
47 This cross-sectional, population-based study highlights the amount by which health system costs
48
49 increased significantly with increasing levels of multimorbidity in a publicly financed healthcare
50
51 system. The average and incremental healthcare costs reported in this study could serve as the
52
53 foundation for future health economic evaluation of interventions for preventing and managing
54
55
56
57
58
59
60

1
2
3 multimorbidity. As the relationship between multimorbidity and healthcare costs varies
4
5 according to socio-demographic factors, interventions addressing disparities in healthcare in
6
7 individuals living with multimorbidity may have a potential to reduce total health system costs.
8
9
10

11 12 13 **LIST OF ABBREVIATIONS**

14
15 AMI acute myocardial infarction

16
17 COPD chronic obstructive pulmonary disorder

18
19 GLM generalized linear model

20
21 ICES Institute for Clinical Evaluative Sciences

22
23 OHIP Ontario Health Insurance Plan

24
25 OLS ordinary least-squares regressions
26
27
28
29
30
31

32 **DECLARATIONS**

33 34 **Ethic approval:**

35
36 The study has been approved by the Research Ethics Board at Sunnybrook Health Sciences
37
38 Centre, Toronto, Ontario, Canada.
39
40

41 **Funding:**

42
43 This manuscript was supported through the Health System Performance Research Network
44
45 (HSPRN) by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC grant
46
47 #06034) and through provision of data by the Institute for Clinical and Evaluative Sciences with
48
49 funding from an annual grant by the Ministry of Health and Long-Term Care. The opinions,
50
51 results, and conclusions reported in this paper are those of the authors and are independent of the
52
53
54
55
56
57
58
59
60

1
2
3 funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or Ontario
4 MOHLTC is intended or should be inferred.
5
6
7
8
9

10 At the time this research was conducted, Dr. Thavorn was partially supported by the HSPRN
11 post-doctoral award and the Li Ka Shing post-doctoral award. None of the authors have any
12 conflicts of interest to report.
13
14
15
16
17

18
19
20 **Competing interests:** None
21
22

23
24 **Authors contributions:** WPW was the lead for the conception and creation of the cohort. YB
25 has created the cohorts through data linkages and helped with data analysis and methods. KT
26 interpreted the results and drafted the manuscript. CM, AG, SB, AK, YB, YP and WPW revised
27 the manuscript for important intellectual content and formatting. All authors read and approved
28 the final manuscript.
29
30
31
32
33
34
35

36 **Data sharing statement:** No additional data are available.
37
38

39 **Figure legends:**

40
41 Figure 1. Distribution of total number of population and total health system costs in Ontario from
42 April 1, 2009 to March 31, 2010
43
44

45
46 ■ without selected conditions ■ 1 ■ 2 ■ 3 ■ 4 ■ 5 +
47
48

49 Figure 2. Unadjusted mean total healthcare cost per capita for Ontario adults, by service type,
50 number of conditions and age group from April 1, 2009 to March 31, 2010
51
52

53
54 ■ Physician ■ Hospital ■ Drug ■ Continuing care ■ Others
55
56
57
58
59
60

REFERENCES

1. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. *JCE*. 1998;51(5):367-75.
2. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract*. 2008;14 Suppl 1:28-32.
3. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. *JAMA*. 1996;276(18):1473-9.
4. Schram MT, Frijters D, van de Lisdonk EH, Ploemacher J, de Craen AJ, de Waal MW, et al. Setting and registry characteristics affect the prevalence and nature of multimorbidity in the elderly. *JCE*. 2008;61(11):1104-12.
5. Kone Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The increasing burden and complexity of multimorbidity. *BMC Pub Health*. 2015;15(1):415.
6. Marengoni A, von Strauss E, Rizzuto D, Winblad B, Fratiglioni L. The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. *J Intern Med*. 2009;265(2):288-95.
7. Mondor L, Maxwell CJ, Bronskill SE, Gruneir A, Wodchis WP. The relative impact of chronic conditions and multimorbidity on health-related quality of life in Ontario long-stay home care clients. *Qual Life Res*. 2016.
8. St John PD, Tyas SL, Menec V, Tate R. Multimorbidity, disability, and mortality in community-dwelling older adults. *Can Fam Physician*. 2014;60(5):e272-80.
9. Gijzen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. *JCE*. 2001;54(7):661-74.
10. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA*. 2005;294(6):716-24.

- 1
2
3 11. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the
4 elderly with diabetes: Identification of areas of potential treatment conflicts. *Diabetes Res Clin Pract.*
5 2010;87(3):385-93.
6
7
- 8 12. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple
9 chronic conditions in the elderly. *Arch Intern Med.* 2002;162(20):2269-76.
10
11
- 12 13. Bahler C, Huber CA, Brungger B, Reich O. Multimorbidity, health care utilization and costs in an
13 elderly community-dwelling population: a claims data based observational study. *BMC Health Serv Res.*
14 2015;15:23.
15
16
- 17 14. Carstensen J, Andersson D, Andre M, Engstrom S, Magnusson H, Borgquist LA. How does
18 comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back
19 pain and osteoarthritis. *BMJ Open.* 2012;2(2):e000809.
20
21
- 22 15. Zulman DM, Pal Chee C, Wagner TH, Yoon J, Cohen DM, Holmes TH, et al. Multimorbidity
23 and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System. *BMJ*
24 *Open.* 2015;5(4):e007771.
25
26
- 27 16. Jones AM, Rice N, dUva TB, Balia S. *Modelling health care costs.* Applied Health Economics. 2
28 ed. Oxford: Routledge; 2013.
29
30
- 31 17. Kadam UT, Uttley J, Jones PW, Iqbal Z. Chronic disease multimorbidity transitions across
32 healthcare interfaces and associated costs: a clinical-linkage database study. *BMJ Open.* 2013;3(7).
33
34
- 35 18. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization
36 and costs. *Annu Rev Public Health.* 1999;20:125-44.
37
38
- 39 19. Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, et al. Prevalence
40 of multimorbidity in a geographically defined American population: patterns by age, sex, and
41 race/ethnicity. *Mayo Clin Proc.* 2014;89(10):1336-49.
42
43
- 44 20. Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and
45 multimorbidity in primary care practice: a PPRNet report. *J Am Board Fam Med.* 2013;26(5):518-24.
46
47
- 48 21. Health Canada. *Economic Burden of Illness in Canada.* Ottawa: Health Canada; 1998.
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. *Am Heart J.* 2002;144(2):290-6.
23. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. *Can Respir J.* 2009;16(6):183-8.
24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. *COPD.* 2009;6(5):388-94.
25. Schultz SE, Rothwell DM, Chen Z, Tu K. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. *Chronic Dis Inj Can.* 2013;33(3):160-6.
26. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care.* 2002;25(3):512-6.
27. Guttman A, Nakhla M, Henderson M, To T, Daneman D, Cauch-Dudek K, et al. Validation of a health administrative data algorithm for assessing the epidemiology of diabetes in Canadian children. *Pediatr Diabetes.* 2010;11(2):122-8.
28. Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. *Open Med.* 2007;1(1):e18-26.
29. Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on Person-Level Costing Using Administrative Databases in Ontario Health System Performance Research Network (HSPRN); 2013.
30. Ontario Ministry of Health and Long Term Care. Schedule of Benefits for Physician Services: Consultations and Visits 2014 [Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/a_consul.pdf].
31. Canadian Institute for Health Information. CCRS Technical Document—Ontario RUG Weighted Patient Day Ottawa: Canadian Institute for Health Information; 2014.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
32. Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the Canadian Marginalization Index: a new tool for the study of inequality. *Can J Public Health*. 2012;103(8 Suppl 2):S12-6.
33. Matheson FI, White HL, Moineddin R, Dunn JR, Glazier RH. Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis. *J Epidemiol Community Health*. 2010;64(8):705-13.
34. Nagl A, Witte J, Hodek JM, Greiner W. Relationship between multimorbidity and direct healthcare costs in an advanced elderly population. Results of the PRISCUS trial. *Zeitschrift fur Gerontologie und Geriatrie*. 2012;45(2):146-54.
35. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. *J Gen Intern Med*. 2007;22 Suppl 3:391-5.
36. Kralj B. Measuring Rurality - RIO2008_BASIC:Methodology and Results 2008 [Available from: <https://www.oma.org/Resources/Documents/2008RIO-FullTechnicalPaper.pdf>].
37. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *JHE*. 2001;20(4):461-94.
38. Yoon J, Zulman D, Scott JY, Maciejewski ML. Costs associated with multimorbidity among VA patients. *Med Care*. 2014;52 Suppl 3:S31-6.
39. Guthrie B, Saultz JW, Freeman GK, Haggerty JL. Continuity of care matters. *BMJ*. 2008;337:a867.
40. Kerr EA, Heisler M, Krein SL, Kabeto M, Langa KM, Weir D, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? *J Gen Intern Med*. 2007;22(12):1635-40.
41. Macintyre S, Hunt K, Sweeting H. Gender differences in health: are things really as simple as they seem? *Soc Sci Med*. 1996;42(4):617-24.

- 1
2
3 42. Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R. Age- and gender-related
4 prevalence of multimorbidity in primary care: the Swiss FIRE project. *BMC Fam Pract.* 2012;13:113.
5
6
7 43. Abad-Diez JM, Calderon-Larranaga A, Poncel-Falco A, Poblador-Plou B, Calderon-Meza JM,
8 Sicras-Mainar A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the
9 older population. *BMC Geriatr.* 2014;14:75.
10
11
12 44. Orueta JF, Nuno-Solinis R, Garcia-Alvarez A, Alonso-Moran E. Prevalence of multimorbidity
13 according to the deprivation level among the elderly in the Basque Country. *BMC Pub Health.*
14 2013;13:918.
15
16
17 45. Williamson DL, Stewart MJ, Hayward K, Letourneau N, Makwarimba E, Masuda J, et al. Low-
18 income Canadians' experiences with health-related services: implications for health care reform. *Health*
19 *Policy.* 2006;76(1):106-21.
20
21
22 46. Crawford SM, Sauerzapf V, Haynes R, Forman D, Jones AP. Social and geographical factors
23 affecting access to treatment of colorectal cancer: a cancer registry study. *BMJ Open.* 2012;2(2):e000410.
24
25
26 47. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. *CMAJ.*
27 2016;188(3):182-8.
28
29
30 48. Canadian Institute for Health Information. Prescribed Drug Spending in Canada, 2013: A Focus
31 on Public Drug Programs. Ottawa: Canadian Institute for Health Information; 2014.
32
33
34 49. Stewart M, Fortin M, Britt HC, Harrison CM, Maddocks HL. Comparisons of multi-morbidity in
35 family practice--issues and biases. *Fam Pract.* 2013;30(4):473-80.
36
37
38 50. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases--a systematic
39 review on existing multimorbidity indices. *Ann Fam Med.* 2011;66(3):301-11.
40
41
42 51. Le Reste JY, Nabbe P, Manceau B, Lygidakis C, Doerr C, Lingner H, et al. The European
43 General Practice Research Network presents a comprehensive definition of multimorbidity in family
44 medicine and long term care, following a systematic review of relevant literature. *J Am Med Dir Assoc.*
45 2013;14(5):319-25.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 52. Islam MM, Yen L, Valderas JM, McRae IS. Out-of-pocket expenditure by Australian seniors
4 with chronic disease: the effect of specific diseases and morbidity clusters. BMC Pub Health.
5
6
7 2014;14:1008.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



167x99mm (300 x 300 DPI)

review only



211x136mm (300 x 300 DPI)

Appendix 1. List of diagnosis codes used to define the 16 selected medical conditions

Condition	ICD 9 / OHIP fee codes	ICD 10
AMI*	410	I21, I22
Arthritis - Osteoarthritis	715	M15-M19
Arthritis - Other Arthritis (Synovitis, Fibrositis, Connective tissue disorders, Ankylosing spondylitis, Gout Traumatic arthritis, pyogenic arthritis, Joint derangement, Dupuytren's contracture, Other MSK disorders)	727, 729, 710, 720, 274, 716, 711, 718, 728, 739	M00-M03, M07, M10, M11-M14, M20-M25, M30-M36, M65-M79
Arthritis - Rheumatoid arthritis	714	M05-M06
Asthma*	493	J45
Cancer	140-239	C00-C26, C30-C44, C45- C97,
Cardiac Arrhythmia	427.3 (DAD) / 427 (OHIP)	I48.0, I48.1
CHF*	428	I500, I501, I509
COPD*	491, 492, 496	J41, J43, J44
Dementia	290, 331, 797 (OHIP) / 290.0, 290.1, 290.3, 290.4, 290.8, 290.9, 294.1, 294.8, 294.9, 331.0, 331.1, 331.2, 797 (DAD)	F000, F001, F002, F009, F010, F011, F012, F013, F018, F019, F020, F021, F022, F023, F024, F028, F03, F051, F065, F066, F068, F069, F09, G300, G301, G308, G309, G310, G311, R54
Depression	311, 300, 296	F32, F33, F412, F480
Diabetes*	250	E08 - E13
Hypertension*	401, 402, 403, 404, 405	I10, I11, I12, I13, I15
Osteoporosis	733	M81 M82
Renal failure	403, 404, 584, 585, 586, v451	N17, N18, N19, T82.4, Z49.2, Z99.2
Stroke	430, 431, 432, 434, 436	I60-I64
Coronary syndrome (excluding MI)	411-414	I20, I22-I25

Note: * validated diagnosis codes; OHIP, Ontario Health Insurance Plan; AMI, Acute Myocardial Infarction, MSK, musculoskeletal; DAD, Discharge Abstract Database; CHF, Congestive Heart Failure; COPD, Chronic Obstructive Pulmonary Disease; MI, Myocardial infarction

Appendix 2. Proportions and mean number of medical conditions by baseline characteristics,

April 1, 2009 to March 31, 2010

	N	Number of medical conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
All cohort	6,639,089	52.2	24.2	12.3	6.1	5.2	1.88 (1.16)
Sex							
Female	3,541,644	49.2	25.3	13.4	6.6	5.5	1.94 (1.18)
Male	3,097,445	55.6	22.8	11.1	5.5	5.0	1.81 (1.14)
Age (years)							
0-19	809,782	89.8	9.3	0.8	0.1	0.01	1.11 (0.35)
20-34	908,634	77.2	18.8	3.4	0.5	0.1	1.27 (0.55)
35-44	875,680	66.5	24.4	7.0	1.7	0.5	1.45 (0.74)
45-64	2,410,603	47.0	29.9	14.4	5.7	3.0	1.88 (1.05)
65-74	836,640	25.3	29.3	22.3	12.7	10.4	2.53 (1.28)
70-74	383,237	21.8	28.2	23.2	14.2	12.6	2.68 (1.30)
75+	797,750	13.6	22.4	23.2	17.8	23.0	3.14 (1.36)
Income quintile							
Lowest	1,249,664	50.3	23.8	12.8	6.8	6.3	1.95 (1.21)
Middle-low	1,307,725	50.8	24.3	12.8	6.5	5.7	1.92 (1.18)
Middle	1,317,644	52.4	24.2	12.2	6.1	5.1	1.87 (1.15)
Middle-high	1,365,082	53.2	24.3	12.0	5.8	4.8	1.85 (1.13)
Highest	1,340,912	53.5	24.5	11.9	5.7	4.5	1.83 (1.12)
Rurality index							
Non-rural (< 40)	6,038,705	52.3	24.1	12.3	6.1	5.2	1.88 (1.56)
Rural (≥40)	514,225	48.9	25.0	13.3	6.8	5.9	1.96 (1.19)
Deprivation quintile							
Least deprived	1,654,445	55.0	24.0	11.4	5.3	4.3	1.80 (1.11)
Less deprived	1,504,855	52.6	24.4	12.2	5.9	4.9	1.86 (1.14)
Somewhat deprived	1,328,459	51.1	24.4	12.7	6.4	5.5	1.91 (1.17)
Very deprived	1,101,586	50.0	24.3	13.0	6.7	6.0	1.94 (1.20)
Most deprived	934,094	50.0	23.8	12.9	6.8	6.4	1.96 (1.21)

Appendix 2. (Cont'd)

	N	Number of medical conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
Instability quintile							
Least unstable	1,715,922	56.6	24.0	11.0	4.9	3.5	1.75 (1.06)
Less unstable	1,365,580	53.2	24.4	12.1	5.8	4.6	1.84 (1.13)
Somewhat unstable	1,077,375	50.5	24.6	12.9	6.5	5.5	1.91 (1.17)
Very unstable	1,195,108	50.4	24.2	12.8	6.6	6.0	1.94 (1.20)
Most unstable	1,169,454	47.3	23.9	13.6	7.6	7.6	2.04 (1.26)
Dependency quintile							
Least dependent	1,400,521	59.3	23.3	10.0	4.3	3.1	1.69 (1.02)
Less dependent	1,456,755	55.5	24.1	11.3	5.2	4.0	1.78 (1.09)
Somewhat dependent	1,280,391	52.4	24.5	12.3	5.9	4.9	1.86 (1.14)
Very dependent	1,134,858	49.3	24.7	13.3	6.8	5.9	1.95 (1.19)
Most dependent	1,250,914	42.2	24.6	15.3	8.9	9.0	2.18 (1.31)
Ethnic concentration quintile							
Lowest	848,456	47.2	25.1	13.9	7.3	6.5	2.01 (1.22)
Middle-low	1,060,646	49.8	24.8	13.0	6.6	5.7	1.91 (1.19)
Middle	1,160,097	51.0	24.5	12.6	6.3	5.5	1.91 (1.17)
Middle-high	1,323,040	53.4	24.0	11.8	5.8	5.0	1.84 (1.14)
Highest	2,131,200	54.9	23.5	11.5	5.5	4.6	1.81 (1.12)
Primary care model							
Family health teams/ other primary care models	1,109,443	51.0	24.9	12.6	6.3	5.2	1.94 (1.28)
Family health networks /family health organizations	1,054,714	49.6	25.3	13.1	6.5	5.5	1.97 (1.30)
Community health centres/family health groups/non-rostered patients	4,474,932	53.1	23.7	12.0	6.0	5.2	1.90 (1.29)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7-9
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9-12
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	7-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12-13
		(b) Describe any methods used to examine subgroups and interactions	13
		(c) Explain how missing data were addressed	Not report
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Not report

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	Not report
		(c) Consider use of a flow diagram	Not report
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13-15
		(b) Indicate number of participants with missing data for each variable of interest	Not report
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not report
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	14-17
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16-17
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20
Discussion			
Key results	18	Summarise key results with reference to study objectives	24-27
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	27
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	27
Generalisability	21	Discuss the generalisability (external validity) of the study results	28
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	29-30

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based, Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017264.R2
Article Type:	Research
Date Submitted by the Author:	03-Aug-2017
Complete List of Authors:	Thavorn, Kednapa; The Ottawa Hospital Research Institute; Institute for Clinical Evaluative Sciences, ICES @uOttawa Maxwell, Colleen; University of Waterloo, Schools of Pharmacy; Institute for Clinical Evaluative Sciences Gruneir, Andrea; University of Alberta, Department of Family Medicine; Institute for Clinical Evaluative Sciences Bronskill, Susan; Institute for Clinical and Evaluative Sciences ; University of Toronto, Canada Bai, YuQing; Institute for Clinical and Evaluative Sciences Koné Pefoyo, Anna; Lakehead University, Department of Health Sciences; University of Toronto, Dalla Lana School of Public Health Petrosyan, Yelena; University of Toronto, Institute of Health Policy, Management and Evaluation Wodchis, Walter; University of Toronto, Institute of Health Policy Management and Evaluation
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health economics
Keywords:	multimorbidity, health system cost, socio-demographic factors, population-based study, publicly funded healthcare system

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**The Effect of Socio-demographic Factors on
the Association between Multimorbidity and Healthcare Costs: A Population-based,
Retrospective Cohort Study**

Kednapa Thavorn PhD^{1,2,3}, Colleen J. Maxwell PhD^{3,4}, Andrea Gruneir PhD^{3,5,6,7}, Susan E. Bronskill PhD^{3,5},
YuQing Bai MSc³, Anna J. Koné Pefoyo PhD^{8,9}, Yelena Petrosyan MD, MPH, PhD⁵,
Walter P. Wodchis PhD^{*3,5,10}

1 Ottawa Hospital Research Institute, The Ottawa Hospital;
2 School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa;
3 Institute for Clinical Evaluative Sciences;
4 Schools of Pharmacy, University of Waterloo;
5 Institute of Health Policy, Management and Evaluation, University of Toronto;
6 Women's College Research Institute, Women's College Hospital;
7 Department of Family Medicine, University of Alberta;
8 Department of Health Sciences, Lakehead University;
9 Dalla Lana School of Public Health, University of Toronto;
10. Toronto Rehabilitation Institute

Kednapa Thavorn, PhD
Ottawa Hospital Research Institute,
The Ottawa Hospital, 501 Smyth Road,
PO Box 201B, Ottawa, ON, Canada K1H 8L6
Email: kthavorn@ohri.ca

Colleen J. Maxwell, PhD
School of Pharmacy, University of Waterloo
10A Victoria St. S., PHR 4013
Kitchener, Ontario, Canada N2G 1C5
Email: colleen.maxwell@uwaterloo.ca

Andrea Gruneir PhD
Department of Family Medicine
Faculty of Medicine and Dentistry
6-40 University Terrace
Edmonton, Alberta Canada T6G 1C9
Email: gruneir@ualberta.ca

Susan E. Bronskill PhD
Institute for Clinical and Evaluative Sciences
G1 06, 2075 Bayview Avenue
Toronto, Ontario, Canada M4N 3M5
Email: susan.bronskill@ices.on.ca

1
2
3
4
5 YuQing Bai, MSc
6 Institute for Clinical and Evaluative Sciences (ICES UofT)
7 155 College Street, Suite 424
8 Toronto, Ontario, Canada M5T 3M6
9 **Email:** yuqing.bai@utoronto.ca
10

11
12 Anna J. Koné Pefoyo, PhD
13 Department of Health Sciences
14 Lakehead University
15 955 Oliver Rd
16 Thunder Bay, Ontario, P7B 5E1 Canada
17 **Email:** akonepe@lakeheadu.ca
18
19

20
21 Yelena Petrosyan, PhD (c)
22 Institute of Health Policy, Management and Evaluation
23 155 College Street
24 Toronto, Ontario, Canada M5T 3M6
25 **Email:** yelena.petrosyan@mail.utoronto.ca
26

27
28 Walter P. Wodchis, PhD, MAE, MA
29 Associate Professor
30 Institute of Health Policy, Management and Evaluation
31 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5 Canada
32 **Email:** walter.wodchis@utoronto.ca
33

34 ***Correspondence:**

35 **Address:**

36 Walter P. Wodchis, PhD, MAE, MA
37 Associate Professor
38 Institute of Health Policy, Management and Evaluation
39 University of Toronto, 155 College Street, Toronto, Ontario M5T 3M5
40 **Tel:** 416-946-7387
41 **Email:** walter.wodchis@utoronto.ca
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To estimate the attributable costs of multimorbidity and assess whether the association between the level of multimorbidity and health system costs varies by socio-demographic factors in young (<65) and older (≥ 65) adults living in Ontario, Canada.

Design: a population-based, retrospective cohort study

Setting: the province of Ontario, Canada

Participants: 6,639,089 Ontarians who were diagnosed with at least one of 16 selected medical conditions on April 1, 2009.

Main outcome measures: From the perspective of the publicly funded healthcare system, total annual healthcare costs were derived from linked provincial health administrative databases using a person-level costing method. We used generalized linear models to examine the association between the level of multimorbidity and healthcare costs and the extent to which socio-demographic variables modified this association.

Results: Attributable total costs of multimorbidity ranged from \$377 to \$2,073 for young individuals and \$1,026 to \$3,831 for older adults. The association between the degree of multimorbidity and healthcare costs was significantly modified by age ($p < 0.001$), sex ($p < 0.001$) and neighborhood income ($p < 0.001$) in both age groups, and the positive association between healthcare costs and levels of multimorbidity was statistically stronger for older than younger adults. For individuals aged 65 years or younger, the increase in healthcare costs was more gradual in women than in their male counterparts, however, for those aged 65 years or older, the increase in healthcare costs was significantly greater among women than men. Lastly, we also observed that the positive association between the level of multimorbidity and healthcare costs was significantly greater at higher levels of marginalization.

1
2
3
4
5 **Conclusion:** Socio-demographic factors are important effect modifiers of the relationship
6
7 between multimorbidity and healthcare costs and should therefore be considered in any
8
9 discussion of the implementation of healthcare policies and the organization of healthcare
10
11 services aimed at controlling healthcare costs associated with multimorbidity.
12
13

14
15
16 **KEYWORDS:** multimorbidity, health system costs, socio-demographic factors, population-
17
18 based study, publicly funded healthcare system
19

20
21 **Word Counts:** 299 (abstract), 4,000 (main text)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This population-based study was based on a large sample size and used robust costing and generalized linear model regression techniques.
- The availability of linked and patient-level health administrative databases allows the estimation of the total health system costs associated with multimorbidity from all healthcare sectors.
- The use of health administrative databases can also minimize potential recall and non-response biases that are commonly found in survey data.
- The total healthcare costs reported in this study may be underestimated because they were derived based on 16 selected medical conditions. Moreover, it was not possible to measure certain costs (e.g., deductibles and co-payments borne by supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated with caregiving) with our data.
- The study did not take into account particular clusters of medical conditions. It is possible that the relationship between multimorbidity and healthcare costs may vary according to the types and patterns of comorbid medical conditions.

BACKGROUND

Multimorbidity, the presence of two or more co-existing conditions within a single person, is increasingly prevalent due to advances in life-extending medical treatments and increases in life expectancy. (1, 2) Internationally, the prevalence of multimorbidity has been shown to range from 17% in young adults (3) to 82% in older adults living in nursing homes. (4) In the province of Ontario, Canada, the prevalence of multimorbidity based on 16 selected conditions rose from 17.4% in 2003 to 24.3% in 2009, and this increase was evident across all age groups. (5)

Higher levels of multimorbidity are associated with impaired physical functioning (6), poorer quality of life (7), more frequent use of health services, and higher risk of death. (8) In addition, individuals with multimorbidity may experience faster disease progression and require more complex medical care. (9) Consequently, these individuals may be at a higher risk of receiving sub-optimal care (10), inappropriate prescriptions (11) and experiencing potentially preventable hospitalizations. (12) These adverse health outcomes can impose a substantial burden on patients, family caregivers, and the healthcare system.

The relationship between multimorbidity and healthcare costs is well-documented and has been shown to be curvilinear or exponential across jurisdictions. The average Medicare payments in the US ranged from \$1,154 among Part A and Part B beneficiaries with one chronic condition to \$13,973 among beneficiaries with at least four chronic conditions (a 12-fold difference). (12) Similarly, the mean total health system costs among older adults with multimorbidity in Switzerland were nearly six times higher than among those without multimorbidity. (13)

1
2
3
4
5 Despite an abundance of research describing the relationship between multimorbidity and
6 healthcare costs, existing studies have some important methodological and conceptual
7 limitations. Some previous studies (14, 15) used Ordinary Least Squares (OLS) regression
8 despite the fact that the positively skewed distribution of cost data often violates the normality
9 assumption of OLS. (16) Others attempted to overcome this problem by transforming cost data
10 to the logarithmic scale (13, 17); however, this transformation may still result in interpretation
11 problems, as regression on transformed costs provides the prediction of a median instead of the
12 arithmetic mean costs. (18) Importantly, the role of socio-demographic characteristics as effect
13 modifiers of the relationship between multimorbidity and healthcare costs remains poorly
14 described, although previous research has shown that the specific types of disease clusters vary
15 by age and sex (2, 19) and that multimorbidity is more prominent in selected visible minority and
16 low-socioeconomic status populations. (20)
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 The objectives of this study were, therefore, to estimate the health system costs attributable to
36 multimorbidity using a more rigorous and appropriate approach, and to assess the extent to
37 which the relationship between the level of multimorbidity and health system costs varies
38 according to socio-demographic characteristics.
39
40
41
42
43
44
45
46

47 **METHODS**

48 **Study design and sample**

49 This population-based, retrospective cohort study included all residents of the province of
50 Ontario between April 1, 2001 and March 31, 2010, who were enrolled in the Ontario Health
51 Insurance Plan (OHIP), and were diagnosed with at least one of the following selected 16
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

medical conditions between April 1, 2001 and March 31, 2009 (study index date): acute myocardial infarction (AMI), arthritis, asthma, cancer, cardiac arrhythmia, chronic coronary syndrome, chronic obstructive pulmonary disorder (COPD), congestive heart failure, dementia, depression, diabetes, hypertension, osteoporosis, renal failure, rheumatoid arthritis and stroke. These conditions were selected because previous research and clinical experts agreed that they were highly prevalent and represented a substantial care and economic burden for Canada's healthcare system.(5, 21) We excluded individuals if they met the following criteria: had an invalid health card number, were older than 105 years, died or moved out of the province prior to the index date. Individuals with no contact with the healthcare system within the past five years prior to the index date were also excluded (excepting infants), as they may have left the province or experienced an unreported death.

Data Sources

We linked multiple provincial health administrative databases anonymously using unique encrypted identifiers. The Discharge Abstract Database provides data for all hospital discharges in Ontario, and the Ontario Health Insurance Plan (OHIP) claims database includes billing claims for all physician encounters. We used the Registered Persons Database to identify Ontarians who were eligible for health insurance coverage and derive their age. The linked database was housed and secured at the Institute for Clinical Evaluative Sciences (ICES) under data security and privacy policies and procedures approved by the Information and Privacy Commissioner of Ontario. This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

1
2
3
4 Each medical condition was defined using diagnostic algorithms and consultation codes that
5
6 have been validated or used in previous studies. We defined six conditions (AMI, asthma,
7
8 chronic heart failure, COPD, diabetes, and hypertension) based on validated population-derived
9
10 registries held at ICES. (22-28) These conditions were all defined based on one diagnosis
11
12 recorded in acute care or two diagnoses recorded in ambulatory care (physician) records within a
13
14 two-year period (i.e. between 2007/8 and 2008/09), except for AMI, which was defined using
15
16 acute care records in 2008/09. A similar approach was adopted to define the remaining medical
17
18 conditions including arthritis, cancer, cardiac arrhythmia, chronic coronary syndrome, dementia,
19
20 depression, osteoporosis, renal failure, rheumatoid arthritis, and stroke. A list of diagnostic codes
21
22 used to define these medical conditions are shown in Appendix 1.
23
24
25
26
27
28
29

30 **Measures**

31 *Healthcare costs*

32
33 Healthcare costs were estimated from the perspective of the publicly funded healthcare system;
34
35 accordingly, only direct costs borne to the Ontario Ministry of Health and Long-Term Care were
36
37 considered. In Ontario, medically necessary hospital and physician services are paid for by the
38
39 publicly-financed health insurance plan, however, public coverage for prescription drugs is
40
41 primarily limited to residents aged 65 years and over, social assistance recipients as well as those
42
43 with high prescription drug costs compared to their net household income.
44
45
46
47
48
49

50
51 We identified, measured and valued direct healthcare costs by applying a person-level costing
52
53 technique that was developed and validated based on the Ontario health administrative data. (29)

54
55 We calculated the costs of inpatient hospitalizations, emergency department visits, same day
56
57
58
59
60

1
2
3
4
5 surgeries, and inpatient rehabilitation by multiplying the weighted volume of services by the
6
7 average provincial costs per weighted case. We obtained the costs of fee-for-service physician
8
9 and outpatient diagnostic or laboratory services through OHIP fee approved as outlined in the
10
11 Ontario Health Insurance Schedule of Benefits and Fees. (30) Non-fee-for-service physician
12
13 payments were calculated by applying applicable capitation payments or the median amount
14
15 reimbursed for the same service code for the specific fiscal year. (29) Costs for high-cost medical
16
17 device equipment were estimated from the amount reimbursed to patients recorded in the
18
19 Assistive Devices Program database. Complex continuing care and inpatient psychiatric costs
20
21 were based on case mix, number of days in care, and Resource Utilization Groups. (31) Patient
22
23 costs for long-term care were estimated based on a fixed per diem according to prevailing
24
25 government payment rates, and costs for home care were estimated using the average cost per
26
27 hour. We used pharmacy payments recorded in the Ontario Drug Benefit database to capture
28
29 prescription medication costs for individuals eligible for public coverage. Annual total direct
30
31 healthcare costs were the sum of costs across healthcare sectors for each patient for a one-year
32
33 period after the study index date, i.e. from April 2009 to March 2010.
34
35
36
37
38
39
40
41

42 We categorized healthcare costs into five components: physician, hospital, drug, continuing care
43
44 and other healthcare delivery costs. Physician costs included professional fees paid by the
45
46 provincial insurance plan directly to physicians in private practice. Hospital costs included
47
48 amounts paid to healthcare institutions, including those providing acute care, extended and
49
50 chronic care, rehabilitation and convalescent care, psychiatric care, as well as drugs dispensed in
51
52 hospitals. Drug costs consisted of the costs of prescriptions dispensed at outpatient pharmacies to
53
54 individuals eligible for provincial coverage while continuing care costs included expenditure on
55
56
57
58
59
60

1
2
3
4 home care and residential long-term (nursing-home) care. The other healthcare delivery costs
5
6 category represented expenditures on an assistive device program that subsidizes high-cost
7
8 equipment, such as wheel chairs, walkers, continuous positive airway pressure devices and
9
10 insulin pumps, for patients with physical disabilities. All costs were expressed in 2009 Canadian
11
12 Dollars.
13
14

15 16 17 18 19 *Independent variables*

20
21 Multimorbidity was defined as the occurrence of two or more chronic diseases among the 16
22
23 selected conditions within a single individual and was categorized into five groups. A categorical
24
25 variable was created to capture those with no multimorbidity (single disease only), two, three,
26
27 four and five or more multimorbid conditions. Socio-demographic variables included age, sex,
28
29 income, and level of marginalization. As prescription drug costs among Ontarians aged less than
30
31 65 years were primarily covered by private drug plans, we ran separate regressions for younger
32
33 (<65 years) and older (65+ years) cohorts, and also included a continuous variable for age in the
34
35 models. Income level was categorized into five quintiles, with the lowest quintile reflecting the
36
37 lowest income level. We used the Ontario Marginalization Index, a validated census- and
38
39 geographically-based index, as a proxy for individual-level socio-demographic factors. (32) The
40
41 index consisted of four dimensions of marginalization: material deprivation; residential
42
43 instability; ethnic concentration; and dependency. Lower scores on each dimension represent
44
45 areas that are the least marginalized and higher scores represent areas that are the most
46
47 marginalized. This index has been shown to be associated with several health outcomes. (33)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 We also controlled for other factors that may confound the impact of multimorbidity on
6
7 healthcare costs, such as the type of primary care model and geographic location. Selection of
8
9 such factors was guided by previous healthcare cost studies (12, 34, 35) and was subject to the
10
11 availability of data on these factors in Ontario administrative databases. The payment scheme of
12
13 primary care services was categorized into three groups: group-based teams with
14
15 capitation/salary and team-based payment (family health teams/other group models); capitation
16
17 or blended payment models (family health networks/family health organizations); or primarily
18
19 fee for service (family health groups and non-rostered patients). Lastly, we assigned a
20
21 geographic location to each individual using the Rurality Index for Ontario (36), whereby a value
22
23 greater than 40 was considered to be a designated rural area.
24
25
26
27
28
29

30 31 **Analysis**

32
33 Annual healthcare costs per capita were described by health service sector, age group (<65 vs.
34
35 ≥ 65 years), the degree of multimorbidity and each of the independent factors, such as sex, age
36
37 group, and level of marginalization. Multivariate regression analyses were used to assess the
38
39 incremental costs of interest in this study. To identify the regression model that best fits the cost
40
41 data, we followed the steps suggested by Manning and Mullahy. (37) We first ran OLS of the
42
43 logarithmic transformation of cost data on the number of medical conditions and other
44
45 confounding factors, however, the OLS regression was deemed inappropriate because the
46
47 residuals were not normally distributed. Therefore, the generalized linear model (GLM) with a
48
49 log-link function and a gamma distribution was chosen because a modified Park test suggested
50
51 that the variance was proportional to the conditional mean. The GLM allows us to estimate mean
52
53 healthcare costs without the need for retransformation.
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Attributable costs due to multimorbidity were estimated by subtracting the mean predicted cost
8 of one medical condition from the mean predicted cost of two conditions, two from three
9 conditions, three from four conditions, and four from at least five conditions, respectively. To
10 investigate whether the relationship between the level of multimorbidity and healthcare costs was
11 moderated by socio-demographic factors, we added two-way interaction terms between the level
12 of multimorbidity and each sociodemographic factor, including sex, age, income level,
13 deprivation quintile, instability quintile, dependency quintile and ethnic concentration quintile.
14 The significance of interaction terms was assessed by comparing the likelihood ratio of the full
15 model with all interaction terms to the model without interaction terms using the likelihood ratio
16 test.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 The model performance, including goodness of fit and specifications, was examined by checking
34 the scaled deviance, Pearson's chi-square statistics and residual plots, respectively. All analyses
35 were performed using SAS statistical software for UNIX (version 9.3; SAS Institute, Cary, North
36 Carolina).
37
38
39
40
41
42
43
44

45 RESULTS

46
47 We identified a cohort of 6,639,089 individuals living with at least one of the selected 16
48 medical conditions in Ontario in 2009 (see Appendix 2 for baseline characteristics). Our cohort
49 represents about 50% of the total population in the province of Ontario in 2009. Close to half of
50 the study cohort (48%) had at least two selected medical conditions, and this prevalence was
51 found to increase with age. The majority of the study cohort was younger than 65 years of age
52
53
54
55
56
57
58
59
60

1
2
3
4 (75%) and just over half was female (53%). Nearly all individuals (91%) resided in non-rural
5
6 areas, and about one-third (33%) lived in neighborhoods with a high proportion of diverse ethnic
7
8 groups.
9
10

11
12
13
14 The total annual healthcare cost estimated for the study cohort was \$26.5 billion. As shown in
15
16 Figure 1, individuals living with at least two selected medical conditions represented 24.4% of
17
18 the total population of Ontario (~13 million) but accounted for approximately two-thirds (67.9%)
19
20 of total allocatable healthcare costs in 2009/10. By contrast, individuals without multimorbidity
21
22 who accounted for 76% of the total population were responsible for only 32.1% of total
23
24 allocatable healthcare costs. On average, annual total costs per capita amounted to \$2,217 in
25
26 individuals younger than 65 years and \$9,398 in those aged 65 years or older.
27
28
29

30
31 [Figure 1]
32

33 Table 1 shows the annual total costs per capita by baseline characteristics for young and older
34
35 adults. For both age groups, per capita total healthcare costs were higher in women than in men.
36
37 The average healthcare costs increased with older age, and greater levels of marginalization were
38
39 associated with higher healthcare costs in both age groups. Mean total healthcare costs were the
40
41 highest among individuals living in the most deprived and most unstable areas as well as those
42
43 who were highly dependent, however, mean total costs decreased as income level increased.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Annual per capita healthcare costs by baseline characteristics and age group, April 1, 2009 to March 31, 2010

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
All cohort	5,004,699	2,217 (9630)	502 (193-1317)	1,634,390	9,398 (19,796)	2,982 (1,448-7,178)
Sex						
Female	2,618,591	2,311 (9,044)	624 (248– 1,546)	923,053	9,526.96 (19,245)	2,991.97 (1,461-7,344)
Male	2,386,108	2,113 (10,233)	378.67 (132– 1,058)	711,337	9,230.31 (20,488)	2,968.13 (1,431-6,982)
Age group (years)						
<20	809,782	997 (6,420)	257 (103-600)			
20 - 44	1,784,314	1,835 (7,997)	440 (155-1,171)			
45 – 64	3,247,243	2,910 (11,414)	684 (291-1,725)			
65 - 74				1,219,877	6,424 (16,464)	2,363 (1,173-4,757)
75+				797,750	12,517 (22,351)	3,964 (1,884-12,277)
Income quintile						
Lowest	935,048	2,822 (11,333)	580 (206-1699)	314,616	10,646 (21,501)	3,325 (1,596-8,667)
Middle-low	970,797	2,360 (10,276)	521 (199-1,380)	336,928	9,529 (20,218)	3,053 (1,501-7,296)
Middle	999,087	2,107 (9,146)	498 (195-1,268)	318,557	9,319 (19,552)	2,992 (1,470-7,114)
Middle-high	1,042,284	2,008 (8,899)	487 (195-1,226)	322,798	9,120 (19,279)	2,916 (1,426-6,873)
Highest	1,009,890	1,903 (8,391)	475 (192-1,180)	331,022	8,549 (18,309)	2,747 (1,351-6,352)
Rurality index						
Non-rural	4,579,691	2,206 (9,605)	509 (197-1,320)	1,459,014	9,448 (19,998)	3,005 (1,470-7,161)
Rural	356,361	2,522 (10,112)	501 (197-1,441)	157,864	9,333 (18,303)	2,918 (1,400-7,798)
Deprivation quintile						

	< 65 years (N=5,004,699)			≥ 65 years (N= 1,634,390)		
	N	Per capita healthcare cost (\$)		N	Per capita healthcare cost (\$)	
		mean (SD)	median (IQR)		mean (SD)	median (IQR)
Least deprived	1,282,898	1,894.17 (8,596.59)	476 (193-1,170)	371,547	9,167 (19,628)	2,823 (1,380-6,709)
Less deprived	1,136,731	2,015 (8,810)	489 (196-1,231)	368,124	8,935 (18,928)	2,898 (1,423-6,759)
Somewhat deprived	982,133	2,193 (9,240)	504 (196-1,311)	346,326	9,165 (19,300)	2,978 (1,463-7,030)
Very deprived	808,152	2,438 (10,281)	511 (200-1,443)	293,434	9,541 (19,951)	3,100 (1,520-7,467)
Most deprived	705,593	2,941 (11,861)	600 (210-1,79)	228,501	10,517 (21,250)	3,326 (1,599-8,570)
Instability quintile						
Least dependent	1,211,734	2,007 (8,674)	489 (188-1,250)	188,787	8,149 (19,413)	2,713 (1,307-5,882)
Less dependent	1,179,936	2,078 (9,134)	500 (195-1,275)	276,819	8,359 (18,652)	2,777 (1,353-6,167)
Somewhat dependent	976,538	2,230 (9,793)	506 (198-1,320)	303,853	8,717 (19,018)	2,849 (1,401-6,548)
Very dependent	808,196	2,349 (9,954)	515 (201-1,375)	326,662	9,068 (19,195)	2,944 (1,458-6,958)
Most dependent	739,103	2,650 (10,947)	550 (213-1,507)	511,811	10,961 (20,953)	3,381 (1,636-9,336)
Ethnic concentration quintile						
Lowest	564,476	2,398 (9,766)	500 (200-1,370)	283,980	9,309 (18,529)	2,983 (1,463-7,533)
Middle-low	756,120	2,288 (9,552)	491 (196-1,317)	304,526	9,170 (18,773)	2,969 (1,458-7,283)
Middle	854,573	2,280 (9,780)	497 (196-1,317)	305,524	9,540 (19,678)	3,011 (1,478-7,419)
Middle-high	1,028,876	2,190 (9,565)	502 (195-1,309)	294,164	9,600 (20,240)	3,012 (1,473-7,266)
Highest	1,711,462	2,124 (9,468)	528 (199-1,331)	419,738	9,288 (20,751)	2,981 (1,441-6,694)

Note: SD, standard deviation; IQR, interquartile range

Figure 2 illustrates the distribution of total cost per capita by type of services. Among individuals younger than 65 years of age, hospitalization was the primary cost driver and responsible for 47% of total healthcare costs, followed by physician costs (32%), drug costs (10%), and

1
2
3
4 continuing care costs (6%). For older adults, hospital costs remained the largest cost component
5
6 (41%), followed by continuing care costs (23%), drug costs (19%) and physician costs (15%).
7
8
9 Figure 2 also reveals that unadjusted mean total costs increased with additional numbers of
10
11 medical conditions, ranging from \$1,352 in individuals younger than 65 years of age without
12
13 multimorbidity to \$13,105 in those living with five or more medical conditions, corresponding to
14
15 a 10-fold increase. On the other hand, while \$4,185 was spent on older adults without
16
17 multimorbidity, spending increased by about 5-fold to \$19,196 in those living with five or more
18
19 medical conditions.
20
21
22

23 [Figure 2]

24
25
26 Table 2 shows adjusted attributable costs of multimorbidity after controlling for other factors.
27
28 Among individuals younger than 65 years, the attributable total cost was \$377 in those living
29
30 with two medical conditions and \$2,073 in those living with at least 5 medical conditions,
31
32 corresponding to a six-fold increase in attributable cost. Similarly, attributable total costs in
33
34 older adults also rose with increasing number of medical conditions, ranging from \$1,026 in
35
36 those with two medical conditions to \$3,831 in those with five or more. The magnitude of an
37
38 incremental cost, however, depended on the reference category. Specifically, one additional
39
40 medical condition in young adults without multimorbidity led to an attributable cost of \$377,
41
42 while for young adults who already had three medical conditions, one additional health condition
43
44 resulted in a total cost of \$798. These incremental costs were even greater in older adults, among
45
46 whom the incremental cost rose from \$1,026 (1 vs. 2 conditions) to \$1,652 (3 vs. 4 conditions).
47
48
49 Similar patterns were observed for subdivided healthcare costs, which varied across age groups
50
51
52 [Table 2]. An additional medical condition caused a 1- to 3-fold increase in the costs of each
53
54
55
56
57
58
59
60

1
2
3
4 health sector except for hospital care, for which incremental costs increased steadily from \$185
5
6
7 to \$802 in the younger cohort and \$232 to \$1,060 in the older adult cohort.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Adjusted incremental total healthcare costs by the degree of multimorbidity and age group*, April 1, 2009 to March 31, 2010

conditions	< 65 years (N=5,004,699)						≥ 65 years (N=1,634,390)					
	total (\$)	physician (\$)	hospital (\$)	drug (\$)	continuing care (\$)	Others (\$)	total (\$)	physician (\$)	hospital (\$)	drug (\$)	continuing care (\$)	others (\$)
2 vs. 1	376.50	200.26	185.12	232.37	288.71	23.96	1,025.76	166.48	231.60	350.29	254.14	23.54
3 vs. 2	534.34	238.28	207.22	252.84	207.83	23.81	1,279.96	201.20	247.76	403.56	314.91	28.51
4 vs. 3	798.03	286.29	264.75	316.43	234.58	24.67	1,651.92	227.04	353.60	429.01	367.45	33.17
≥5 vs. 4	2,072.57	515.80	801.64	666.13	486.58	37.64	3,831.40	400.57	1060.00	673.89	732.19	63.76

*adjusted for sex, age, income quintile, primary care model, rurality index, deprivation quintile, instability quintile, dependency quintile, and ethnic concentration quintile

1
2
3 We also found that the association between the number of medical conditions (i.e. the degree of
4 multimorbidity) and healthcare costs was significantly modified by age and sex for both young
5 and older adults [Table 3], and the positive association between healthcare costs and levels of
6 multimorbidity was significantly stronger for older than younger adults. For individuals aged 65
7 years or younger, the increase in healthcare costs was more gradual in women than in their male
8 counterparts, however, among those aged 65 years or older, the increase in healthcare costs in
9 women was significantly greater than in men.
10
11
12
13
14
15
16
17
18
19

20
21
22 For both age groups, we observed small interaction effects between the number of medical
23 conditions and other socio-demographic factors. The rise in healthcare costs with as the level of
24 multimorbidity increased was less pronounced among high-income individuals than low-income
25 individuals, and the association between the level of multimorbidity and healthcare costs was
26 significantly modified by the level of deprivation, instability, dependency and ethnic
27 concentration. The positive association between the level of multimorbidity and healthcare costs
28 was stronger among individuals living in more deprived, unstable, dependent or diverse ethnic
29 groups than those living in less deprived, stable, dependent or high concentration of ethnic
30 diversity areas. We did not observe a significant interaction between the number of medical
31 conditions and the level of dependency in the older adult cohort.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Generalized linear models results for total healthcare costs[^]

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
Intercept	1.6844***	0.0007	1.6049***	0.0034
Age	0.0023***	0.0001	0.0053***	0.0001
Sex				
Male	reference		reference	
Female	0.0628***	0.0002	-0.0023***	0.0006
Number of medical conditions				
1 condition	reference		reference	
2 conditions	0.1092***	0.0017	0.1068***	0.0044
3 conditions	0.2189***	0.0027	0.1860***	0.0045
4 conditions	0.3312***	0.0050	0.2563***	0.0049
≥5 conditions	0.4203***	0.0080	0.3772***	0.0048
Income quintile				
Lowest	reference		reference	
Middle-low	-0.0043***	0.0005	-0.0019*	0.0010
Middle	-0.0045***	0.0005	0.00014	0.0012
Middle-high	-0.0044***	0.0006	0.0001	0.0012
Highest	-0.0080***	0.0006	-0.0045***	0.0013
Deprivation quintile				
Least deprived	reference		reference	
Less deprived	-0.0006*	0.0004	-0.0014***	0.0008
Somewhat deprived	-0.0008*	0.0004	-0.0020**	0.0009
Very deprived	0.0022***	0.0005	-0.0009	0.0011
Most deprived	0.0135***	0.0006	0.0044***	0.0013
Instability quintile				
Least unstable	reference		reference	
Less unstable	0.0039***	0.0005	-0.0019**	0.0009
Somewhat unstable	0.0073***	0.0005	-0.0008	0.0009
Very unstable	0.0122***	0.0005	0.0031***	0.0009
Most unstable	0.0247***	0.0005	0.0087***	0.0010
Ethnic concentration quintile				
Lowest	reference		reference	
Middle-low	0.0002	0.0004	-0.0005	0.0009
Middle	0.0018***	0.0004	0.0022	0.0009
Middle-high	0.0047***	0.0004	-0.0007	0.0010
Highest	0.0066***	0.0004	-0.0043***	0.0009
Dependency quintile				
Least dependent	reference		reference	
Less dependent	0.0004	0.0004	0.0012**	0.0005
Somewhat dependent	0.0001	0.0004	0.0027***	0.0005
Very dependent	0.0009**	0.0004	0.0030***	0.0005

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
Most dependent	0.0020***	0.0005	0.0100***	0.0005
Number of medical conditions * sex				
1 condition* Male	reference		reference	
2 conditions * Female	-0.0171***	0.0016	-0.0029***	0.0007
3 conditions * Female	-0.0396***	0.0011	-0.0022***	0.0008
4 conditions * Female	-0.0549***	0.0007	0.0001	0.0008
≥5 conditions * Female	-0.0659***	0.0005	0.0030***	0.0008
Number of medical conditions * age				
1 condition * age	reference		reference	
2 conditions * age	-0.0007***	0.0016	-0.0006***	0.0001
3 conditions * age	-0.0014***	0.0011	-0.0010***	0.0001
4 conditions * age	-0.0022***	0.0007	-0.0014***	0.0001
≥5 conditions * age	-0.0023***	0.0005	-0.0023***	0.0001
Number of medical conditions * income quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0016*	0.0009	-0.0025*	0.0013
3 conditions * middle-low	-0.0011	0.0013	-0.0037**	0.0014
4 conditions* middle-low	-0.0043**	0.0020	-0.0043**	0.0015
≥5 conditions* middle-low	-0.0031	0.0027	-0.0046**	0.0014
2 conditions*middle	-0.0020**	0.0010	-0.0032**	0.0015
3 conditions * middle	-0.0030**	0.0014	-0.0051**	0.0015
4 conditions* middle	-0.0053**	0.0023	-0.0055**	0.0017
≥5 conditions* middle	-0.0028	0.0031	-0.0072***	0.0016
2 conditions*middle-high	-0.0024**	0.0011	-0.0031*	0.0016
3 conditions * middle-high	-0.0032**	0.0016	-0.0052**	0.0016
4 conditions* middle-high	-0.0067**	0.0025	-0.0081***	0.0018
≥5 conditions* middle-high	-0.0093**	0.0034	-0.0070***	0.0018
2 conditions*highest	-0.0015	0.0011	-0.0036**	0.0017
3 conditions * highest	-0.0031*	0.0017	-0.0063***	0.0018
4 conditions* highest	-0.0096***	0.0027	-0.0088***	0.0019
5 conditions* highest	-0.0099**	0.0038	-0.0095***	0.0019
Number of medical conditions * deprivation quintile				
1 condition* lowest	reference		reference	
2 conditions*middle-low	0.0024***	0.0007	-0.0001	0.0011
3 conditions * middle-low	0.0038 ***	0.0010	-0.0015	0.0011
4 conditions* middle-low	0.0027	0.0017	-0.0016	0.0013
≥5 conditions* middle-low	0.0060**	0.0026	-0.0029**	0.0012
2 conditions*middle	0.0047***	0.0007	-0.0002	0.0012
3 conditions * middle	0.0067***	0.0010	-0.0018	0.0013
4 conditions* middle	0.0062***	0.0017	-0.0045**	0.0014
≥5 conditions* middle	0.0109***	0.0026	-0.0042**	0.0014
2 conditions*middle-high	0.0057***	0.0009	-0.0012	0.0014

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
3 conditions * middle-high	0.0071***	0.0014	-0.0031**	0.0015
4 conditions* middle-high	0.0074***	0.0022	-0.0051**	0.0016
≥5 conditions* middle-high	0.0111***	0.0032	-0.0079***	0.0016
2 conditions*highest	0.0073***	0.0011	-0.0028	0.0017
3 conditions *highest	0.0108***	0.0016	-0.0052**	0.0018
4 conditions* highest	0.0114***	0.0026	-0.0089***	0.0019
≥5 conditions* highest	0.0119***	0.0036	-0.0098***	0.0019
Number of medical conditions * instability				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0012**	0.0007	0.0009	0.0011
3 conditions * middle-low	-0.0007	0.0010	0.0020	0.0012
4 conditions* middle-low	-0.0016	0.0017	0.0010	0.0013
≥5 conditions* middle-low	-0.0013	0.0026	0.0022	0.0014
2 conditions*middle	-0.0017**	0.0008	0.0037**	0.0014
3 conditions * middle	-0.0012	0.0012	0.0010	0.0013
4 conditions* middle	-0.0002	0.0019	0.0022	0.0014
≥5 conditions* middle	0.0025	0.0027	0.0037**	0.0014
2 conditions*middle-high	-0.0003	0.0009	0.0022*	0.0012
3 conditions * middle-high	0.0006	0.0012	0.0019	0.0013
4 conditions* middle-high	0.0011	0.0019	0.0033**	0.0014
≥5 conditions* middle-high	0.0075***	0.0027	0.0048***	0.0014
2 conditions*highest	0.0037***	0.0012	-0.0027**	0.0013
3 conditions *highest	0.0095***	0.0012	-0.0026**	0.0013
4 conditions* highest	0.0113***	0.0020	-0.0035**	0.0014
≥5 conditions* highest	0.0206***	0.0028	-0.0019	0.0014
Number of medical conditions * ethnic concentration				
1 condition* lowest	reference		reference	
2 conditions*middle-low	-0.0006	0.0009	0.0011	0.0012
3 conditions * middle-low	-0.0007	0.0013	0.0022*	0.0012
Number of medical conditions * ethnic concentration				
4 conditions* middle-low	-0.0020	0.0021	0.0012	0.0014
≥5 conditions* middle-low	0.0018	0.0029	0.0012	0.0013
2 conditions*middle	0.0004	0.0009	0.0006	0.0012
3 conditions * middle	-0.0006	0.0013	0.0003	0.0012
4 conditions* middle	-0.0034	0.0021	-0.0012	0.0014
≥5 conditions* middle	0.0016	0.0030	0.0004	0.0013
2 conditions*middle-high	0.0002	0.0009	0.0015	0.0012
3 conditions * middle-high	-0.0013	0.0014	0.0021*	0.0013
4 conditions* middle-high	-0.0056**	0.0022	0.0006	0.0014
≥5 conditions* middle-high	-0.0056*	0.0030	0.0035**	0.0014
2 conditions*highest	-0.0008	0.0012	0.0043***	0.0012
3 conditions *highest	-0.0021	0.0013	0.0047***	0.0013

	< 65 years (N=5,004,699)		≥ 65 years (N=1,634,390)	
	coefficient	se	coefficient	se
4 conditions* highest	-0.0081***	0.0021	0.0044***	0.0013
≥5 conditions* highest	-0.0070**	0.0030	0.0093***	0.0013
Number of medical conditions * dependency quintile[#]				
1 condition* lowest	reference		reference	
2 conditions* middle-low	0.0016**	0.0007		
3 conditions * middle-low	0.0018**	0.0010		
4 conditions* middle-low	0.0004	0.0017		
≥5 conditions* middle-low	-0.0028	0.0026		
2 conditions* middle	0.0015**	0.0001		
3 conditions * middle	0.0030***	0.0011		
4 conditions* middle	0.0036**	0.0018		
≥5 conditions* middle	0.0008	0.0025		
2 conditions* middle-high	0.0017**	0.0008		
3 conditions * middle-high	0.0029**	0.0012		
4 conditions* middle-high	0.0028	0.0019		
≥5 conditions* middle-high	0.0014	0.0027		
2 conditions* highest	0.0018**	0.0009		
3 conditions * highest	0.0032**	0.0013		
4 conditions* highest	0.0041**	0.0020		
≥5 conditions* highest	0.0038	0.0028		
AIC	15,672,974		5,058,276	
BIC	15,674,535		5,059,515	

^ adjusted for primary care models and rurality index; *** P < 0.001, ** P < 0.05, * p < 0.10; se indicates standard error; # interaction between the number of medical conditions and dependency quintile was not statistically significant and therefore excluded from a final model.

DISCUSSION

Individuals living with multimorbidity accounted for 79% of total healthcare costs incurred by our study cohort and 68% of total allocatable healthcare costs in Ontario in 2009. Although there is a growing body of literature documenting the economic burden of multimorbidity in other jurisdictions (12, 13, 38), the current study provides further evidence that the relatively small proportion of the population with multimorbid conditions is responsible for a disproportionately high percentage of total healthcare costs. Moreover, we observed this disproportionate

1
2
3 relationship in both young (<65) and (65+) older cohorts, suggesting that any approaches to
4
5 containing the healthcare costs of multimorbidity should be implemented across all age groups.
6
7
8
9

10 Our study demonstrated that healthcare costs increased significantly with higher levels of
11
12 multimorbidity, and that this positive association exists even after the adjustment for
13
14 confounding factors and a skewed distribution of cost data using the generalized linear model
15
16 with a log link function and a gamma distribution. The exponential relationship between
17
18 multimorbidity and incremental healthcare costs shown in this study suggests that the financial
19
20 burden of multimorbidity to the healthcare system is not simply equal to the sum of costs
21
22 incurred by each individual condition. This non-linearity reflects the complex association of the
23
24 degree of multimorbidity, the type of disease clusters and healthcare costs. It is likely that
25
26 patients with multimorbidity might experience worse health outcomes and require more complex
27
28 clinical management.⁽⁹⁾ They are also vulnerable to receiving redundant diagnostic tests (12), a
29
30 suboptimal level of continuity of care, and inappropriate prescriptions, (11) as current treatment
31
32 guidelines are mainly focused on individual disease management. (10) Thus, as the number of
33
34 healthcare providers involved in the patient's care increases, information sharing and
35
36 coordinating care across healthcare providers may become increasingly challenging. (39)
37
38 Moreover, an increasing number of comorbid conditions may compromise patients' ability to
39
40 self-manage their diseases. (40) Therefore, the high healthcare spending on multimorbidity found
41
42 in our study underscores the need for ensuring continuity and coordination of care in this
43
44 population.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 More importantly, our study contributes to the understanding of the association between the
4 degree of multimorbidity and healthcare costs. We observed that each unit increase in age
5 amplified the rise in healthcare costs associated with an increasing number of medical
6 conditions. The observed interaction effect may partly be due to patterns in healthcare use among
7 the older population, which is often characterized by poly-pharmacy and the use of continuing
8 care services that are very costly. Additionally, we found that the positive association between
9 healthcare costs and levels of multimorbidity was stronger in men than in women among
10 individuals younger than 65 years. This sex difference might relate to the prevalence of different
11 disease clusters in men and women, as men within this age group often experience life-
12 threatening and more serious illnesses than women. (41, 42) For those older than 65 years, the
13 increase in healthcare costs observed with the increase in the level of multimorbidity was
14 significantly higher in women than men. This sex difference could be partially explained by
15 longer life expectancy and greater risk of multimorbidity in older women than men (20, 43),
16 which may cause older women to be more dependent on formal (paid) healthcare services and
17 other informal (unpaid) caregivers.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 We observed small interaction effects of neighborhood-level socioeconomic characteristics on
42 the association between the number of medical conditions and healthcare costs. Living in lower
43 income and marginalized areas, i.e. areas with greater levels of instability, dependency or ethnic
44 concentration, accelerated the increase in health system costs with increased multimorbidity.
45 This may reflect a higher risk of experiencing more complex multimorbid conditions among
46 individuals living in disadvantaged neighborhoods, (44) in turn leading to greater demand for
47 and utilization of healthcare. Another plausible explanation for this phenomenon is that
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 individuals living in more deprived areas may face barriers to accessing health services (45) and
4
5 therefore have delayed access to preventive healthcare interventions or treatments (46),
6
7 consequently being at greater risk of developing poorer health outcomes and incurring higher
8
9 healthcare costs. The effects of socioeconomic factors reported in this study should however be
10
11 interpreted with caution, as they were derived based on neighborhood. Although the interaction
12
13 terms between socioeconomic factors and levels of multimorbidity were statistically significant,
14
15 most of the estimated effect sizes were very small and may be a result of the large sample size
16
17 used in this study.
18
19
20
21
22
23

24 **Strengths and limitations**

25
26 This population-based study was based on a large sample size and used robust costing and
27
28 generalized linear model regression techniques. The availability of linked and patient-level
29
30 health administrative databases allowed the estimation of the total health system costs associated
31
32 with multimorbidity from all healthcare sectors, and the use of health administrative databases
33
34 minimized potential recall and non-response biases that are commonly found in survey data.
35
36
37
38
39

40
41 Nonetheless, the results of this study should be interpreted in light of the following limitations.

42
43 First, we estimated healthcare costs based on 16 selected medical conditions, and this selection
44
45 of a limited number of medical conditions is likely to underestimate the overall healthcare costs
46
47 of multimorbidity. However, total cost estimates reported in our study were comprehensive, as
48
49 they amounted to 86% of total allocatable government expenditures in Ontario in 2009.(47)
50
51

52
53 Secondly, due to a paucity of data, certain costs (e.g., deductibles and co-payments borne by
54
55 supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated
56
57
58
59
60

1
2
3 with caregiving) were excluded from the analysis. In addition, this study could not capture the
4 costs of medications covered by private sectors, including private insurers and out of pocket
5 expenses, which at the time of the study represented the largest component of total prescription
6 drug costs of Canadians who are younger than 65 years of age. (48) For this reason, findings
7 from this study may not be generalizable to other jurisdictions with different healthcare systems.
8
9

10
11
12
13
14
15
16
17
18 Third, this study did not take into account clusters of medical conditions. It is possible that the
19 relationship between multimorbidity and healthcare costs may vary according to the type and
20 patterns of comorbid medical conditions; which should be investigated in future studies. We
21 chose to use disease counts in the present study, as there are no standards or guidelines for the
22 definition or measurement of multimorbidity, and the choice of the measure would be subject to
23 data availability and the outcome of interest. (49, 50) A previous study conducted by our team
24 (5) has shown, however, that there was no common clustering of diseases among individuals
25 living with multimorbidity, as the number of disease clusters required to include 80% of the
26 study population increased from 14 (among individuals with two conditions) to 2,744 clusters of
27 conditions (among individuals with 5 or more conditions), thus supporting the use of disease
28 counts rather than clusters. Moreover, a previous systematic review showed that 132 definitions
29 of multimorbidity with 1,631 criteria were used in the published literature. (51) Our decision to
30 use disease counts is also supported by a study by Islam et al. (52) indicating that the total
31 number of chronic conditions were more predictive of out-of-pocket healthcare costs and high-
32 cost users than disease clusters, dominant groups or dominant pairs.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSION

This population-based, retrospective cohort study highlights the amount by which health system costs increased significantly with increasing levels of multimorbidity in a publicly-financed healthcare system. The average and incremental healthcare costs reported in this study could serve as the foundation for future health economic evaluation of interventions for preventing and managing multimorbidity. As the relationship between multimorbidity and healthcare costs varies according to socio-demographic factors, interventions addressing disparities in healthcare in individuals living with multimorbidity may have the potential to reduce total health system costs.

LIST OF ABBREVIATIONS

AMI acute myocardial infarction

COPD chronic obstructive pulmonary disorder

GLM generalized linear model

ICES Institute for Clinical Evaluative Sciences

OHIP Ontario Health Insurance Plan

OLS ordinary least-squares regressions

DECLARATIONS

Ethics approval:

The study has been approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Funding:

This manuscript was supported through the Health System Performance Research Network (HSPRN) by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC grant #06034) and through provision of data by the Institute for Clinical and Evaluative Sciences with funding from an annual grant by the Ministry of Health and Long-Term Care. The opinions, results, and conclusions reported in this paper are those of the authors and are independent of the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or Ontario MOHLTC is intended or should be inferred.

At the time this research was conducted, Dr. Thavorn was partially supported by the HSPRN post-doctoral award and the Li Ka Shing post-doctoral award. None of the authors have any conflicts of interest to report.

Competing interests: None

Authors contributions: WPW was the lead for the conception and creation of the cohort. YB created the cohorts through data linkages and helped with data analysis and methods. KT and WW drafted the manuscript. KT, CM, AG, SB, AK, YB, YP, and WPW interpreted the results and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Data sharing statement: No additional data are available.

Figure legends:

Figure 1. Distribution of total number of population and total health system costs in Ontario from April 1, 2009 to March 31, 2010

■ without selected conditions ■ 1 ■ 2 ■ 3 ■ 4 ■ 5 +

1
2
3 Figure 2. Unadjusted mean total healthcare cost per capita for Ontario adults, by service type,
4 number of conditions and age group from April 1, 2009 to March 31, 2010
5
6
7

8 ■ Physician ■ Hospital ■ Drug ■ Continuing care ■ Others
9
10
11
12
13

14 REFERENCES

- 15
16 1. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general
17 practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. *JCE*.
18 1998;51(5):367-75.
19
20
21 2. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last
22 20 years. *Eur J Gen Pract*. 2008;14 Suppl 1:28-32.
23
24 3. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs.
25 *JAMA*. 1996;276(18):1473-9.
26
27 4. Schram MT, Frijters D, van de Lisdonk EH, Ploemacher J, de Craen AJ, de Waal MW, et al.
28 Setting and registry characteristics affect the prevalence and nature of multimorbidity in the elderly. *JCE*.
29 2008;61(11):1104-12.
30
31 5. Kone Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The
32 increasing burden and complexity of multimorbidity. *BMC Pub Health*. 2015;15(1):415.
33
34 6. Marengoni A, von Strauss E, Rizzuto D, Winblad B, Fratiglioni L. The impact of chronic
35 multimorbidity and disability on functional decline and survival in elderly persons. A community-based,
36 longitudinal study. *J Intern Med*. 2009;265(2):288-95.
37
38 7. Mondor L, Maxwell CJ, Bronskill SE, Gruneir A, Wodchis WP. The relative impact of chronic
39 conditions and multimorbidity on health-related quality of life in Ontario long-stay home care clients.
40 *Qual Life Res*. 2016.
41
42 8. St John PD, Tyas SL, Menec V, Tate R. Multimorbidity, disability, and mortality in community-
43 dwelling older adults. *Can Fam Physician*. 2014;60(5):e272-80.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 9. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and
4 consequences of comorbidity: a review. *JCE*. 2001;54(7):661-74.
5
- 6
7 10. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality
8 of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA*.
9 2005;294(6):716-24.
10
- 11
12 11. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the
13 elderly with diabetes: Identification of areas of potential treatment conflicts. *Diabetes Res Clin Pract*.
14 2010;87(3):385-93.
15
- 16
17 12. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple
18 chronic conditions in the elderly. *Arch Intern Med*. 2002;162(20):2269-76.
19
- 20
21 13. Bahler C, Huber CA, Brungger B, Reich O. Multimorbidity, health care utilization and costs in an
22 elderly community-dwelling population: a claims data based observational study. *BMC Health Serv Res*.
23 2015;15:23.
24
- 25
26 14. Carstensen J, Andersson D, Andre M, Engstrom S, Magnusson H, Borgquist LA. How does
27 comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back
28 pain and osteoarthritis. *BMJ Open*. 2012;2(2):e000809.
29
- 30
31 15. Zulman DM, Pal Chee C, Wagner TH, Yoon J, Cohen DM, Holmes TH, et al. Multimorbidity
32 and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System. *BMJ*
33 *Open*. 2015;5(4):e007771.
34
- 35
36 16. Jones AM, Rice N, dUva TB, Balia S. Modelling health care costs. *Applied Health Economics*. 2
37 ed. Oxford: Routledge; 2013.
38
- 39
40 17. Kadam UT, Uttley J, Jones PW, Iqbal Z. Chronic disease multimorbidity transitions across
41 healthcare interfaces and associated costs: a clinical-linkage database study. *BMJ Open*. 2013;3(7).
42
- 43
44 18. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization
45 and costs. *Annu Rev Public Health*. 1999;20:125-44.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


19. Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. *Mayo Clin Proc.* 2014;89(10):1336-49.
20. Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. *J Am Board Fam Med.* 2013;26(5):518-24.
21. Health Canada. *Economic Burden of Illness in Canada.* Ottawa: Health Canada; 1998.
22. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. *Am Heart J.* 2002;144(2):290-6.
23. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. *Can Respir J.* 2009;16(6):183-8.
24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. *COPD.* 2009;6(5):388-94.
25. Schultz SE, Rothwell DM, Chen Z, Tu K. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. *Chronic Dis Inj Can.* 2013;33(3):160-6.
26. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care.* 2002;25(3):512-6.
27. Guttmann A, Nakhla M, Henderson M, To T, Daneman D, Cauch-Dudek K, et al. Validation of a health administrative data algorithm for assessing the epidemiology of diabetes in Canadian children. *Pediatr Diabetes.* 2010;11(2):122-8.
28. Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. *Open Med.* 2007;1(1):e18-26.
29. Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on Person-Level Costing Using Administrative Databases in Ontario Health System Performance Research Network (HSPRN); 2013.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Ontario Ministry of Health and Long Term Care. Schedule of Benefits for Physician Services: Consultations and Visits 2014 [Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/a_consul.pdf].
31. Canadian Institute for Health Information. CCRS Technical Document—Ontario RUG Weighted Patient Day Ottawa: Canadian Institute for Health Information; 2014.
32. Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the Canadian Marginalization Index: a new tool for the study of inequality. *Can J Public Health*. 2012;103(8 Suppl 2):S12-6.
33. Matheson FI, White HL, Moineddin R, Dunn JR, Glazier RH. Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis. *J Epidemiol Community Health*. 2010;64(8):705-13.
34. Nagl A, Witte J, Hodek JM, Greiner W. Relationship between multimorbidity and direct healthcare costs in an advanced elderly population. Results of the PRISCUS trial. *Zeitschrift fur Gerontologie und Geriatrie*. 2012;45(2):146-54.
35. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. *J Gen Intern Med*. 2007;22 Suppl 3:391-5.
36. Kralj B. Measuring Rurality - RIO2008_BASIC:Methodology and Results 2008 [Available from: <https://www.oma.org/Resources/Documents/2008RIO-FullTechnicalPaper.pdf>].
37. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *JHE*. 2001;20(4):461-94.
38. Yoon J, Zulman D, Scott JY, Maciejewski ML. Costs associated with multimorbidity among VA patients. *Med Care*. 2014;52 Suppl 3:S31-6.
39. Guthrie B, Saultz JW, Freeman GK, Haggerty JL. Continuity of care matters. *BMJ*. 2008;337:a867.

- 1
2
3 40. Kerr EA, Heisler M, Krein SL, Kabeto M, Langa KM, Weir D, et al. Beyond comorbidity counts:
4 how do comorbidity type and severity influence diabetes patients' treatment priorities and self-
5 management? *J Gen Intern Med.* 2007;22(12):1635-40.
6
7
8
9
10 41. Macintyre S, Hunt K, Sweeting H. Gender differences in health: are things really as simple as
11 they seem? *Soc Sci Med.* 1996;42(4):617-24.
12
13
14 42. Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R. Age- and gender-related
15 prevalence of multimorbidity in primary care: the Swiss FIRE project. *BMC Fam Pract.* 2012;13:113.
16
17
18 43. Abad-Diez JM, Calderon-Larranaga A, Poncel-Falco A, Poblador-Plou B, Calderon-Meza JM,
19 Sicras-Mainar A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the
20 older population. *BMC Geriatr.* 2014;14:75.
21
22
23
24 44. Orueta JF, Nuno-Solinis R, Garcia-Alvarez A, Alonso-Moran E. Prevalence of multimorbidity
25 according to the deprivation level among the elderly in the Basque Country. *BMC Pub Health.*
26 2013;13:918.
27
28
29
30
31 45. Williamson DL, Stewart MJ, Hayward K, Letourneau N, Makwarimba E, Masuda J, et al. Low-
32 income Canadians' experiences with health-related services: implications for health care reform. *Health*
33 *Policy.* 2006;76(1):106-21.
34
35
36
37 46. Crawford SM, Sauerzapf V, Haynes R, Forman D, Jones AP. Social and geographical factors
38 affecting access to treatment of colorectal cancer: a cancer registry study. *BMJ Open.* 2012;2(2):e000410.
39
40
41
42 47. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. *CMAJ.*
43 2016;188(3):182-8.
44
45
46
47 48. Canadian Institute for Health Information. Prescribed Drug Spending in Canada, 2013: A Focus
48 on Public Drug Programs. Ottawa: Canadian Institute for Health Information; 2014.
49
50
51 49. Stewart M, Fortin M, Britt HC, Harrison CM, Maddocks HL. Comparisons of multi-morbidity in
52 family practice--issues and biases. *Fam Pract.* 2013;30(4):473-80.
53
54
55
56 50. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases--a systematic
57 review on existing multimorbidity indices. *Ann Fam Med.* 2011;66(3):301-11.
58
59
60


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
51. Le Reste JY, Nabbe P, Manceau B, Lygidakis C, Doerr C, Lingner H, et al. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. *J Am Med Dir Assoc.* 2013;14(5):319-25.
52. Islam MM, Yen L, Valderas JM, McRae IS. Out-of-pocket expenditure by Australian seniors with chronic disease: the effect of specific diseases and morbidity clusters. *BMC Pub Health.* 2014;14:1008.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



167x99mm (300 x 300 DPI)

review only



211x136mm (300 x 300 DPI)

Appendix 1. List of diagnosis codes used to define the 16 selected medical conditions

Condition	ICD 9 / OHIP fee codes	ICD 10
AMI*	410	I21, I22
Arthritis - Osteoarthritis	715	M15-M19
Arthritis - Other Arthritis (Synovitis, Fibrositis, Connective tissue disorders, Ankylosing spondylitis, Gout Traumatic arthritis, pyogenic arthritis, Joint derangement, Dupuytren's contracture, Other MSK disorders)	727, 729, 710, 720, 274, 716, 711, 718, 728, 739	M00-M03, M07, M10, M11-M14, M20-M25, M30-M36, M65-M79
Arthritis - Rheumatoid arthritis	714	M05-M06
Asthma*	493	J45
Cancer	140-239	C00-C26, C30-C44, C45- C97,
Cardiac Arrhythmia	427.3 (DAD) / 427 (OHIP)	I48.0, I48.1
CHF*	428	I500, I501, I509
COPD*	491, 492, 496	J41, J43, J44
Dementia	290, 331, 797 (OHIP) / 290.0, 290.1, 290.3, 290.4, 290.8, 290.9, 294.1, 294.8, 294.9, 331.0, 331.1, 331.2, 797 (DAD)	F000, F001, F002, F009, F010, F011, F012, F013, F018, F019, F020, F021, F022, F023, F024, F028, F03, F051, F065, F066, F068, F069, F09, G300, G301, G308, G309, G310, G311, R54
Depression	311, 300, 296	F32, F33, F412, F480
Diabetes*	250	E08 - E13
Hypertension*	401, 402, 403, 404, 405	I10, I11, I12, I13, I15
Osteoporosis	733	M81 M82
Renal failure	403, 404, 584, 585, 586, v451	N17, N18, N19, T82.4, Z49.2, Z99.2
Stroke	430, 431, 432, 434, 436	I60-I64
Coronary syndrome (excluding MI)	411-414	I20, I22-I25

Note: * validated diagnosis codes; OHIP, Ontario Health Insurance Plan; AMI, Acute Myocardial Infarction, MSK, musculoskeletal; DAD, Discharge Abstract Database; CHF, Congestive Heart Failure; COPD, Chronic Obstructive Pulmonary Disease; MI, Myocardial infarction

Appendix 2. Proportions and mean number of medical conditions by baseline characteristics,

April 1, 2009 to March 31, 2010

	N	Number of medical conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
All cohort	6,639,089	52.2	24.2	12.3	6.1	5.2	1.88 (1.16)
Sex							
Female	3,541,644	49.2	25.3	13.4	6.6	5.5	1.94 (1.18)
Male	3,097,445	55.6	22.8	11.1	5.5	5.0	1.81 (1.14)
Age (years)							
0-19	809,782	89.8	9.3	0.8	0.1	0.01	1.11 (0.35)
20-34	908,634	77.2	18.8	3.4	0.5	0.1	1.27 (0.55)
35-44	875,680	66.5	24.4	7.0	1.7	0.5	1.45 (0.74)
45-64	2,410,603	47.0	29.9	14.4	5.7	3.0	1.88 (1.05)
65-74	836,640	25.3	29.3	22.3	12.7	10.4	2.53 (1.28)
70-74	383,237	21.8	28.2	23.2	14.2	12.6	2.68 (1.30)
75+	797,750	13.6	22.4	23.2	17.8	23.0	3.14 (1.36)
Income quintile							
Lowest	1,249,664	50.3	23.8	12.8	6.8	6.3	1.95 (1.21)
Middle-low	1,307,725	50.8	24.3	12.8	6.5	5.7	1.92 (1.18)
Middle	1,317,644	52.4	24.2	12.2	6.1	5.1	1.87 (1.15)
Middle-high	1,365,082	53.2	24.3	12.0	5.8	4.8	1.85 (1.13)
Highest	1,340,912	53.5	24.5	11.9	5.7	4.5	1.83 (1.12)
Rurality index							
Non-rural (< 40)	6,038,705	52.3	24.1	12.3	6.1	5.2	1.88 (1.56)
Rural (≥40)	514,225	48.9	25.0	13.3	6.8	5.9	1.96 (1.19)
Deprivation quintile							
Least deprived	1,654,445	55.0	24.0	11.4	5.3	4.3	1.80 (1.11)
Less deprived	1,504,855	52.6	24.4	12.2	5.9	4.9	1.86 (1.14)
Somewhat deprived	1,328,459	51.1	24.4	12.7	6.4	5.5	1.91 (1.17)
Very deprived	1,101,586	50.0	24.3	13.0	6.7	6.0	1.94 (1.20)
Most deprived	934,094	50.0	23.8	12.9	6.8	6.4	1.96 (1.21)

Appendix 2. (Cont'd)

	N	Number of medical conditions					Mean (SD)
		1 (%)	2 (%)	3 (%)	4 (%)	≥5 (%)	
Instability quintile							
Least unstable	1,715,922	56.6	24.0	11.0	4.9	3.5	1.75 (1.06)
Less unstable	1,365,580	53.2	24.4	12.1	5.8	4.6	1.84 (1.13)
Somewhat unstable	1,077,375	50.5	24.6	12.9	6.5	5.5	1.91 (1.17)
Very unstable	1,195,108	50.4	24.2	12.8	6.6	6.0	1.94 (1.20)
Most unstable	1,169,454	47.3	23.9	13.6	7.6	7.6	2.04 (1.26)
Dependency quintile							
Least dependent	1,400,521	59.3	23.3	10.0	4.3	3.1	1.69 (1.02)
Less dependent	1,456,755	55.5	24.1	11.3	5.2	4.0	1.78 (1.09)
Somewhat dependent	1,280,391	52.4	24.5	12.3	5.9	4.9	1.86 (1.14)
Very dependent	1,134,858	49.3	24.7	13.3	6.8	5.9	1.95 (1.19)
Most dependent	1,250,914	42.2	24.6	15.3	8.9	9.0	2.18 (1.31)
Ethnic concentration quintile							
Lowest	848,456	47.2	25.1	13.9	7.3	6.5	2.01 (1.22)
Middle-low	1,060,646	49.8	24.8	13.0	6.6	5.7	1.91 (1.19)
Middle	1,160,097	51.0	24.5	12.6	6.3	5.5	1.91 (1.17)
Middle-high	1,323,040	53.4	24.0	11.8	5.8	5.0	1.84 (1.14)
Highest	2,131,200	54.9	23.5	11.5	5.5	4.6	1.81 (1.12)
Primary care model							
Family health teams/ other primary care models	1,109,443	51.0	24.9	12.6	6.3	5.2	1.94 (1.28)
Family health networks /family health organizations	1,054,714	49.6	25.3	13.1	6.5	5.5	1.97 (1.30)
Community health centres/family health groups/non-rostered patients	4,474,932	53.1	23.7	12.0	6.0	5.2	1.90 (1.29)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7-9
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-12
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	7-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12-13
		(b) Describe any methods used to examine subgroups and interactions	13
		(c) Explain how missing data were addressed	Not report
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Not report

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	Not report
		(c) Consider use of a flow diagram	Not report
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	14-15
		(b) Indicate number of participants with missing data for each variable of interest	Not report
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not report
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	14-17
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17, 19
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20
Discussion			
Key results	18	Summarise key results with reference to study objectives	24-27
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	27
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	27
Generalisability	21	Discuss the generalisability (external validity) of the study results	28
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	30

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.